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  directions,	  (c)	  seed	  2	  offset	  between	  SIM-­‐CT	  and	  deformed	  CBCT,	  (d)	  seed	  2	  offset	  for	  	  	  	  	  the	  rigid	  registration,	  (e)	  seed	  3	  offset	  between	  SIM-­‐CT	  and	  deformed	  CBCT,	  (f)	  seed	  3	  offset	  for	  the	  rigid	  registration.	  ......................................................................................................................	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  Figure	  24:	  DIR	  validation.	  (a)	  SIM-­‐CT	  images	  with	  every	  9mm	  spacing,	  (b)	  corresponding	  	  	  	  	  	  deformed	  CBCT	  images	  (c)	  the	  cropped	  UE	  images	  in	  the	  ROI	  ........................................................	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  Figure	  25:	  Dose	  reconstruction.	  (a)	  dose	  calculated	  on	  CBCT	  (b)	  warped	  dose	  by	  applying	  transformation	  matrix	  (c)	  resample	  dose	  to	  match	  dose	  grid	  size	  in	  SIM-­‐CT	  ...........................	  73	  	  Figure	  26:	  Warped	  dose	  for	  each	  treatment	  session	  was	  accumulated	  to	  generate	  total	  delivered	  	  dose	  at	  any	  fraction	  ..............................................................................................................................................	  74	  	  Figure	  27:	  	  Isodose	  comparison	  between	  plan	  and	  real.	  (a)	  plan	  dose	  distribution	  with	  PTV	  	  	  	  	  	  	  	  margin	  10/6	  mm,	  (b)	  real	  dose	  distribution	  to	  plan	  with	  PTV	  margin	  10/6	  mm,	  (c)	  	  	  	  	  	  	  plan	  dose	  distribution	  with	  PTV	  margin	  	  5/3	  mm,	  (d)	  real	  dose	  distribution	  to	  plan	  	  	  	  	  	  with	  PTV	  margin	  5/3	  mm,	  (e)	  plan	  dose	  distribution	  with	  PTV	  margin	  3	  mm,	  (f)	  real	  	  	  	  dose	  distribution	  to	  plan	  with	  PTV	  margin	  3	  mm.	  ...............................................................................	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  Figure	  28:	  DVH	  comparison	  for	  three	  different	  PTV	  margins	  between	  treatment	  plan	  and	  real	  	  	  	  	  	  	  	  plan	  of	  patient	  1.	  PTV	  is	  pink	  line;	  CTV	  is	  red	  line;	  Rectum	  is	  brown	  line;	  Bladder	  is	  blue	  line.	  (a)	  PTV	  margin	  is	  10/6	  mm;	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  margin	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  5/3	  mm;	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  is	  3mm.	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  78	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Figure	  29:	  DVH	  comparison	  for	  three	  different	  PTV	  margins	  between	  treatment	  plan	  and	  real	  	  	  	  	  	  	  	  plan	  of	  patient	  2.	  PTV	  is	  pink	  line;	  CTV	  is	  red	  line;	  Rectum	  is	  brown	  line;	  Bladder	  is	  	  	  	  	  	  	  	  	  blue	  line.	  (a)	  PTV	  margin	  is	  10/6	  mm;	  (b)	  PTV	  margin	  is	  5/3	  mm;	  (c)	  PTV	  margin	  is	  	  	  	  	  3mm.	  ...........................................................................................................................................................................	  78	  	  Figure	  30:	  DVH	  comparison	  for	  three	  different	  PTV	  margins	  between	  treatment	  plan	  and	  real	  	  	  	  	  	  	  	  plan	  	  	  	  of	  patient	  3.	  PTV	  is	  pink	  line;	  CTV	  is	  red	  line;	  Rectum	  is	  brown	  line;	  Bladder	  is	  	  	  	  	  	  	  blue	  line.	  	  	  	  (a)	  PTV	  margin	  is	  10/6	  mm;	  (b)	  PTV	  margin	  is	  5/3	  mm;	  (c)	  PTV	  margin	  is	  	  	  3mm.	  ...........................................................................................................................................................................	  79	  	  Figure	  31:	  DVH	  comparison	  for	  three	  different	  PTV	  margins	  between	  treatment	  plan	  and	  real	  plan	  	  	  of	  patient	  4.	  PTV	  is	  pink	  line;	  CTV	  is	  red	  line;	  Rectum	  is	  brown	  line;	  Bladder	  is	  blue	  line.	  	  	  	  (a)	  PTV	  margin	  is	  10/6	  mm;	  (b)	  PTV	  margin	  is	  5/3	  mm;	  (c)	  PTV	  margin	  is	  3mm.	  .................	  79	  	  Figure	  32:	  DVH	  comparison	  for	  three	  different	  PTV	  margins	  between	  treatment	  plan	  and	  real	  plan	  	  	  of	  patient	  5.	  PTV	  is	  pink	  line;	  CTV	  is	  red	  line;	  Rectum	  is	  brown	  line;	  Bladder	  is	  blue	  line.	  	  	  	  (a)	  PTV	  margin	  is	  10/6	  mm;	  (b)	  PTV	  margin	  is	  5/3	  mm;	  (c)	  PTV	  margin	  is	  3mm.	  .................	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  Figure	  33:	  TCP	  value	  vs.	  	  α/β	  ratio	  of	  plan	  and	  real	  dose	  delivery	  in	  three	  margins	  for	  patient1.	  N0	  =10000/cm3.	  (a)	  SF2	  is	  0.5.	  TCP	  is	  1	  to	  each	  α/β	  value	  in	  all	  plans;	  (b)	  SF2	  is	  0.6.	  TCP	  difference	  was	  within	  1%	  across	  the	  range	  of	  α/β	  ratio	  in	  each	  plan.	  ..........................................	  81	  	  Figure	  34:	  TCP	  vs.	  N0	  evaluation	  for	  all	  six	  plans	  of	  five	  patients.	  N0	  is	  in	  log	  scale	  ranging	  from	  	  	  	  	  	  103	  to	  106.	  	  TCP	  value	  of	  six	  plans	  was	  compared	  against	  each	  other	  to	  determine	  	  	  margin	  effect	  and	  real	  dose	  delivery	  against	  plan.	  ..............................................................................	  82	  	  Figure	  35:	  Rectum	  EUD	  of	  five	  patients	  based	  on	  Emami’s	  data	  where	  TD50=80Gy,	  n=0.12,	  m=0.15.	  	  Blue	  bar	  represented	  EUD	  based	  on	  real	  dose.	  Red	  bar	  represented	  EUD	  based	  on	  	  	  	  planned	  dose.	  ..........................................................................................................................................................	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  Figure	  36:	  NTCP	  comparison	  of	  rectum	  between	  real	  dose	  and	  planned	  dose	  for	  three	  margins.	  	  	  	  	  Each	  figure	  showed	  real	  NTCP	  (blue)	  vs.	  planned	  NTCP	  (orange).	  The	  marker	  showed	  	  	  	  	  the	  value	  for	  each	  margin.	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  Figure	  37:	  NTCP	  comparison	  of	  late	  rectal	  bleeding	  between	  real	  dose	  and	  planned	  dose	  for	  	  	  	  	  	  	  	  	  	  three	  margins.	  Grade	  2/3	  late	  bleeding	  was	  calculated	  based	  on	  parameters	  whereTD50=81.9Gy,	  n=0.23,	  m=0.19.	  Grade	  3	  late	  bleeding	  was	  calculated	  based	  on	  parameters	  whereTD50=78.6Gy,	  n=0.06,	  m=0.06.	  Markers	  with	  square	  showed	  NTCP	  	  	  	  	  	  	  	  	  of	  grade	  2/3	  bleeding.	  Markers	  with	  triangle	  represented	  NTCP	  of	  grade	  3	  bleeding	  	  	  	  	  	  	  only.	  Pink	  line	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  NTCP	  for	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  2/3	  of	  real	  dose.	  Orange	  line	  was	  NTCP	  for	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  2/3	  	  	  	  of	  planned	  dose.	  Blue	  line	  was	  NTCP	  for	  grade	  3	  of	  real	  dose.	  Red	  line	  was	  NTCP	  	  	  	  	  for	  	  	  	  grade	  3	  of	  planned	  dose.	  .........................................................................................................................	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  Figure	  38:	  Bladder	  EUD	  of	  five	  patients	  based	  on	  Emami’s	  data	  where	  TD50=80Gy,	  n=0.5,	  m=0.11.	  	  Blue	  bar	  represented	  EUD	  based	  on	  real	  dose.	  Red	  bar	  represented	  EUD	  based	  on	  	  	  	  planned	  dose.	  ..........................................................................................................................................................	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  Figure	  39:	  NTCP	  comparison	  of	  bladder	  between	  real	  dose	  and	  planned	  dose	  for	  three	  margins.	  	  	  	  	  Each	  figure	  showed	  real	  NTCP	  (blue)	  vs.	  planned	  NTCP	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  The	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  showed	  	  	  	  	  the	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  for	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  3	  (c)	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  planned	  dose.	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Figure	  40:	  DVH	  comparison	  between	  real	  dose	  and	  planned	  dose	  at	  (a)	  5th	  fraction,	  (b)10th	  	  	  	  	  	  	  fraction,	  (c)	  15th	  fraction,	  (d)20th	  fraction,	  (e)	  25th	  fraction,	  (f)	  30th	  fraction,	  (g)	  35th	  fraction,	  (h)	  42th	  fraction.	  The	  upper	  DVH	  lines	  of	  rectum	  and	  bladder	  showed	  real	  	  	  	  	  	  	  dose	  and	  the	  	  	  	  lower	  ones	  were	  planned	  dose.	  The	  discrepancy	  was	  accumulated	  over	  fractions.	  PTV	  	  	  	  and	  CTV	  DVH	  did	  not	  have	  large	  deviation.	  .............................................................	  91	  	  Figure	  41:	  DVH	  comparison	  planned	  dose	  and	  accumulated	  dose	  at	  every	  ten	  fractions	  plus	  re-­‐optimized	  dose	  for	  the	  remaining	  fractions.	  (a)	  Accumulated	  dose	  at	  10th	  fraction	  plus	  	  	  	  	  re-­‐optimized	  dose	  of	  the	  rest	  32	  fractions.	  (b)	  Accumulated	  dose	  at	  20th	  fraction	  plus	  	  	  	  	  	  	  re-­‐optimized	  dose	  of	  the	  rest	  22	  fractions.	  (c)	  Accumulated	  dose	  at	  30th	  fraction	  plus	  	  	  	  	  	  	  	  re-­‐optimized	  dose	  of	  the	  rest	  12	  fractions.	  (d)	  Accumulated	  dose	  at	  40th	  fraction	  plus	  	  	  	  	  	  	  re-­‐optimized	  dose	  of	  the	  rest	  2	  fractions.	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CHAPTER 1: INTRODUCTION 
1.1 Background 
1.1.1 History 
Radiation was applied into medicine soon after Wilhelm Roentgen 
discovered x-rays in 1895. The first therapeutic procedure using x-rays to treat 
cancer was performed within two months of the discovery.  After only a few years, 
radiotherapy was performed throughout the United Sates for medical treatments. 
However, the major limitation in the early days was to produce high energy beam 
to treat deep seated tumors. X-rays used in the external beam radiotherapy were 
generated at voltages up to 300 kVp until 1950. Megavoltage beams which have 
energy 1MV or greater has become popular after the development of Cobalt-60 
units and high energy machine like linear accelerator (Linac). There have been 
enormous contributions to radiotherapy from radiation oncologists and medical 
physicists since 1960s. Radiotherapy has become one of the primary cancer 
treatment techniques.   
With the development of the Linac, higher energy beams can be 
generated to treat deep seated tumors while providing some skin sparing. 
Depending on tumor position and shape, single or multiple beams can be used in 
the planning. Up until relatively recently the patient treatment setup was done 
either on the therapy unit, or on a therapy unit simulator, which has exactly the 
same coordinate system and accessory mounts as a therapy unit, but with a 
diagnostic KV source in the head instead of the therapeutic MV beam, and with a 
provision to take scalable fluoroscopic and radiographic images or films. The 
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treatment fields are selected during this conventional type of simulation process. 
Portal films are taken from those pre-selected directions to show 2-dimensional 
(2D) information of the patient. The target and organ at risk (OAR) or field 
apertures could be drawn on the film. A hand calculation is typically performed to 
correlate the prescription dose to the target with the beam-on time, typically 
expressed as the dose rate independent Monitor Units (MU).  
With CT units becoming more common in Radiation Oncology 
departments since the late 1980s, patient-specific volumetric information is 
readily available for better organ delineation and targeting. This prompted rapid 
development of CT-based treatment planning systems, 3-dimensional conformal 
radiotherapy (3DCRT) has emerged to improve tumor control while reducing 
dose to normal tissue by utilizing static geometric beam shaping with custom 
blocks or Multileaf Collimators (MLC). The conventional simulation process was 
replaced with a virtual simulation, based on the patient anatomical information 
acquired from the simulation CT scan (SIM-CT). The major difference of the SIM-
CT unit and the diagnostic CT unit is in the ability to select and mark the 
treatment isocenter using external lasers. The treatment isocenter can be 
selected on-line, while the patient is still on the CT table and the corresponding 
alignment marks are tattooed on the patient skin. Alternatively, skin marks can be 
tattooed in a conventional simulation process. BB radio opaque markers are then 
attached to the tattoos, and the diagnostic CT is acquired and transferred into the 
treatment planning system. Then the corresponding treatment isocenter can be 
determined off-line, by localizing BBs in the diagnostic CT using the treatment 
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planning software. The planning flow of 3DCRT consists of setting up treatment 
fields based on the tumor position and surrounding organs at risk, adjusting 
beam shapes and weighting, adding beam modifiers like wedges or boluses, etc., 
calculating dose and reviewing the plan. Volumetric dose coverage (isodose 
lines), and, if volumes are delineated, dose volume histograms (DVH) are 
evaluated as a part of the plan review. If the plan is not satisfactory, the 
parameters can be modified and dose recalculated until an acceptable plan is 
achieved. 
1.1.2 Intensity Modulated Radiation Therapy (IMRT) 
One of the most important developments in radiation oncology is IMRT.  A 
higher degree of dose conformality can be achieved by using IMRT. The inverse 
treatment planning of IMRT usually involves two steps. First the dose distribution 
is optimized to meet the prescription by generating fluence maps of each incident 
beam. Secondly, the actual fluence map is produced from the generated fluence 
by modulating the beam either through physical custom compensators or 
computer controlled MLC. The detailed procedures are described below. 
The number of fields and their incident directions are set empirically by 
either utilizing the treatment planner’s experience or appropriate treatment 
planning algorithms. Then a dose volume based optimization engine determines 
an optimal solution closest to the desired outcome based on the initial field setup. 
The desired outcome is usually set in the form of dose constraints and 
optimization functions for the target and OAR in DVH. The intensity level to each 
beamlet of the field and the relative weights of the fields are optimized to achieve 
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the goal. Ideally, planning target volume (PTV) should be covered by the 
prescription dose completely. However, such attempts could result in largely 
inhomogeneous dose distribution, especially when the PTV shape is irregular 
and strict constraints are placed on the surrounding critical organs.  The common 
practice is to sacrifice PTV coverage by 2-5% to balance the normal tissue DVH 
and dose inhomogeneity.  
Delivery of IMRT can be achieved in several ways. Custom compensators 
and computer controlled MLC are the two most widely used options. A 
compensator can be machined according to transmission values computed from 
a fluence pattern. If it is machined with high spatial resolution then the delivered 
fluence agrees with the one optimized very well. But using the physical 
compensators presents certain inconvenience since they need to be changed for 
each field manually, thus lengthening the treatment time. Also, without proper 
device coding and recognition, it is possible to make a mistake by putting a 
wrong compensator in the field. Computer controlled MLC is the most practical 
way to deliver IMRT. A typical MLC consists of two sets of 40-60 leaves, of 
various thicknesses, depending on the leaf position in the leaf bank, design and 
the manufacturer. The leaf sequencing algorithm calculates a series of MLC 
shaped apertures and a motion pattern to modulate the beam intensity according 
to the optimized fluence map. Depending on the correlation of the MLC 
movement and beam on times, the delivery can be divided into step-shoot and 
dynamic methods.  The dynamic delivery synchronizes the simultaneous leaf 
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motion and radiation delivery while the step-shoot delivery separates the two 
instances.  
1.1.3 Image Guided Radiation Therapy (IGRT) 
The treatment delivery and proper positioning of the patient becomes 
crucial to achieve optimal delivery when using IMRT.  IGRT has been increasing 
the accuracy of target localization using image guidance. This cutting edge 
innovation, combined with IMRT, improves the accuracy in delivering higher 
radiation doses to the tumor. Different techniques have been developed to 
address the tumor inter, intra fraction motion, patient setup uncertainty and 
geometry variation etc. Several systems are currently available commercially. 
The modern Linacs like Trilogy (Varian Medical Systems, Palo Alto, CA), 
Synergy (Elekta AB, Stockholm, SE) or Artiste (Siemens Medical Solution, 
Malvern, PA) have a KV x-ray source and a flat panel imager mounted on the 
gantry in addition to the conventional MV electronic portal imaging device (EPID). 
The radiographic or fluoroscopic images can be acquired before and during the 
treatment using these imaging devices. It provides high contrast images to match 
DRR generated from planning CT with very low dose. The imaging window and 
level can be adjusted and filtered correspondingly for better view of certain 
anatomical structures. KV images are especially useful in setting up the 
treatment isocenter relative to bony structures or implanted fiducial markers. The 
drawback is it only contains 2D image without volume information and it is 
difficult to visualize any soft tissue. 
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Cone-Beam CT (CBCT) can be generated by reconstructing 300-600 
projection 2D images acquired with KV or MV imagers through a range of gantry 
rotation. CBCT provides 3D volumetric patient information at the treatment 
position with good soft tissue contract to achieve precise localization and 
treatment setup. A 3D CBCT image can be reconstructed and viewed in minutes 
with fast algorithms. The use of large radiographic detectors can achieve bigger 
field of view coverage with high spatial resolution. CBCT can be registered to 
SIM-CT by matching bony anatomy or soft tissues.  Couch translational and 
angular corrections can be performed automatically at the treatment console 
using couch robotics.  
CT on rail is another IGRT system that has a conventional CT scanner in 
the treatment room that travels on two parallel rails thus allowing acquiring a 3D 
image of a patient in the treatment position. It shares the same couch with the 
Linac. The pre-treatment CT can be registered to the planning CT to correct for 
the daily variations in the setup and patient internal anatomy. Since it is a fan 
beam CT, the image quality is much better than CBCT with less scatter and 
shading artifacts.  
Ultrasound (US) uses transducer to perform a limited scan of a patient 
body with high frequency sound. The returning echoes from the tissues in the 
body are collected by the transducer. The images are produced by identifying 
structures with different acoustic properties. US imaging is a noninvasive medical 
test without any ionizing radiation. It does not produce any radiation side effects 
to the patient. But US image resolution and contrast is not compatible with CT 
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images. Limited volume of the US image acquisition also presents challenges 
with defining rotational corrections. 
 The Calypso 4D localization system is designed to track tumor motion 
during the patient treatment and to perform the 3-point setup without exposing a 
patient to extra dose of radiation. The 3 beacon passive electromagnetic 
transponders are permanently implanted into specific regions of the target. Each 
transponder has a unique response signal which is detected by flat panel 
antenna array to determine the position of the target by triangulation of the 
signals. The system can be used for localization and tracking of target motion.  It 
also allows adjusting the patient position continuously during radiation delivery to 
compensate for motion that exceeds pre-set tolerance levels.     
With the implementation of IGRT, the traditional PTV margin used to 
account for setup uncertainties can be further reduced. Therefore, exposure to 
organs at risk can be reduced even further. It also improves the accuracy of 
targeting the tumor and opens additional possibilities for dose escalation and the 
next generation of treatment – Adaptive Radiation Therapy (ART).  
1.1.4 Adaptive Radiation Therapy (ART) 
ART can utilize daily CT or CBCT imaging to track anatomical changes, 
such as displacement and deformation in the target and surrounding tissues, and 
to adopt the treatment plan for optimal delivery accordingly. It is a closed loop 
system consolidating image guidance, deformable image registration (DIR), dose 
reconstruction, dose calculation and re-optimization. It can compensate for 
uncertainties related to organ deformation, inter-fraction setup errors, and 
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previous deviations in dosimetric deliveries. In order to implement ART clinically, 
there are many technical issues to be addressed, including improved image 
quality of CBCT, accurate dose calculation on CBCT, deformable image 
registration, and dose reconstruction. Also current clinical practices need to 
adapt the new methodology accordingly such as the optimal treatment margin for 
ART and cost effective schedule for reoptimization. Even though it is still in the 
early stages of development, ART shows the potential to be a comprehensive 
treatment strategy for achieving optimal radiation treatment.  
1.2  Specific Aims 
The goal of this investigation is to establish the framework of ART for 
prostate cancer treatment which is one of prevailing cancers among men in the 
United States. The specific aims are as follows: 
a) To measure extra dose delivered to patients from daily localization 
using CBCT  
b) To show that dose calculation on 3D CBCT image is accurate enough 
for treatment planning 
c) To validate DIR for co-registering SIM-CT and CBCT and verify the 
registration accuracy 
d) To compare the difference between planed and delivered doses 
predicted from dose deformation based on patient’s geometrical 
variation , and its effect on tumor control and normal tissue 
complication using DVH and radiobiological model 
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e) To discuss the margin reduction and suggest an optimal margin for 
prostate cancer treatments after implementing ART for clinical use 
f) To evaluate re-optimization schedule which balance labor intensity and 
ideal treatment delivery 
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CHAPTER 2: DOSE DELIVERED FROM CBCT TO 
PROSTATE CANCER PATIENTS 
 
2.1 Introduction 
 CBCT using the on-board imager (OBI) device installed on a Linac allows 
three-dimensional (3D) online patient setup and treatment verification. Use of 
CBCT enables isocenter localization using soft tissue imaging, which provides a 
major advantage for prostate and surrounding tissues visualization on a daily 
basis. 2D localization based on pelvic bony landmarks using either OBI or portal 
imaging is less accurate (Schallenkamp, et al. 2005). In our institution, a clinical 
protocol has been implemented using CBCT (Varian Medical Systems, Palo Alto, 
CA) for daily prostate patient setup. Patients were treated to a total of 75.6 Gy in 
42 fractions using the IMRT technique. Further, patients were educated about a 
dietary and bowel regimen to assure an empty rectum prior to simulation and 
treatments. If upon acquiring the CBCT during the treatment setup the rectum 
was found not empty or with gas, causing the displacement of the prostate or 
affecting the image quality, the patient was taken off the treatment table and 
instructed to use the restroom. A second CBCT was then acquired prior to 
treatment and used for localization and shifts. The accumulated total-body dose 
delivered from such CBCT use can be much higher than that from simulation CT 
and conventional EPID use. The goal of this study is to measure the daily CBCT 
dose. 
 The computed tomography dose index (CTDI) that is used to represent 
the diagnostic CT dose may not be adopted for the specification of CBCT dose 
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(CTDI is even considered less adequate for multi-slice CT scanners (Dixon 2003) 
(Brenner 2005). The reasons are: (1) the 10 cm long ion chamber used to 
measure the CTDI for diagnostic CT cannot collect all scatters from the large 
cone opening of CBCT; (2) the cumulative dose from CBCT may be high and the 
dose distribution is better measured and added to the treatment dose and (3) 
CBCT is quite different from diagnostic CT in terms of gantry rotational speed, 
bowtie design, etc. A measurement of CBCT dose has been recently reported 
(Islam, et al. 2006) for Elekta’s Synergy system. In that study, patients’ skin dose, 
phantom surface dose and phantom center dose (two cylindrical phantoms: 16 
and 32 cm diameters) were measured at different technical settings and different 
field-of-views using MOSFET detectors and a Farmer chamber. 
 In this study, we measured the extra dose to the patients from daily 
localization using CBCT with standard imaging technique and fixed collimator 
settings. Skin doses for seven prostate patients were measured. TLD capsules 
were placed on the patient’s skin at the central axis of three beams: AP, left 
lateral (Lt Lat) and right lateral (Rt Lat). In order to avoid an imaging artifact 
consisting of a number of concentric rings superimposed on the prostate, the 
treatment couch was dropped 3 cm from the patient’s tattoo (i.e. central axis).  
This imaging artifact was fixed in the later releases of the image reconstruction 
algorithms. The surface doses on an IMRT phantom (CIRS, Norfolk, VA) (oval 
shaped: 20 cm AP and 30 cm Lat dimensions) were then measured to verify the 
lateral dose asymmetry noticed from in-vivo measurements on patients. A Rando 
pelvic phantom was used to measure the in-phantom dose distributions along the 
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AP and Lat central axis, including the surface doses. Phantom dose 
measurements were made for both the table-drop (3 cm) and central-axis setups 
in order to check the difference between the two. The absorbed dose was 
determined using the data provided by AAPM TG61 (Ma, Coffey, et al. 2001).  
2.2 Materials and Methods 
2.2.1 Varian’s OBI system and OBI-based CBCT 
 
 Varian’s on-board imager (OBI) device was installed on a dual energy 
21EX linear accelerator (Linac). The OBI system consisted of a kV x-ray source 
(KVS) and an amorphous-silicon (a-Si) flat panel detector (KVD) in addition to 
the megavoltage electronic portal imaging device (EPID). The KVS and KVD 
were mounted on the Linac gantry via two robotically controlled arms, which 
position the KVS and KVD orthogonally to the treatment beam and retract when 
they are not in use. The x-ray tube (KVS) has two focal spots: smaller size of 0.4 
mm and larger size of 0.8 mm. The x-rays can be delivered in two modes: 
radiographic mode and pulsed-fluoro mode. The KVD panel has a detection area 
of 40 cm (X) × 30 cm (Y). With the panel set at 150 cm source-to-detector 
distance (SDD), the maximum superior/inferior coverage is 20 cm at the 
isocenter plane. 
 OBI-based CBCT was acquired by rotating the Linac gantry from 175° to 
185° in the extension mode for a total of 370° rotation. The kV source always 
starts from patient’s Lt Lat and ends at Lt Lat resulting in a 10° over scan on the 
Lt Lat side. CBCT has two acquisition modes to offer two different field-of-views: 
full-fan mode and half-fan mode. Full-fan mode was used to scan sites where 
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the size is less than 24 cm (e.g., brain). KVD is centered in this mode. Half-fan 
mode was used for sites larger than 24 cm (mostly for body scans) and KVD 
was shifted to one side to cover more than half the patient’s volume. Bowtie 
filters for either mode can be mounted to the KVS to modify the beam profile for 
less patient dose. Figure 1 shows a schematic of the two different modes. 
 
Figure 1: CBCT acquisition mode. (a) Full-fan mode with full bowtie mounted. The KVD is centered 
with x-ray axis. (b) Half-fan mode with half bowtie mounted. The KVD is shifted to one side. 
 
2.2.2 Setup for CBCT dose measurement 
 For all scans, a technical setting of 125 kV, 80 mA and 25 ms was used. 
X-rays were delivered in pulsed-fluoro mode. CBCT scans were acquired in half-
fan mode using a half bowtie. In this mode, the flat panel detector was shifted to 
one side and the collimators were set at X1 = 5.3 cm and X2 = 24.9 cm. Y1 and 
Y2 were set both at 6 cm. Note that the maximum Y coverage is 20 cm at the 
source-to-detector distance (SDD) of 150 cm. 12 cm scan in the longitudinal 
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direction was a good compromise between decreasing scatter and patient 
overage for prostate localization. 
 Skin doses for seven prostate patients undergoing daily CBCT were 
measured. TLD capsules were placed on the patient’s tattoo, i.e., the central axis 
of three beams: AP, Lt Lat and Rt Lat. To avoid the ring artifacts centered at the 
prostate, the treatment couch was dropped 3 cm from the patient’s tattoo (Fig. 
2(a) is the central-axis setup and 2(b) is the table-drop setup. The rings around 
the central axis in 2(a) moved 3 cm anterior in 2(b)). After the Lt Lat dose was 
found higher than the Rt Lat dose, we measured the surface doses at the same 
three sites on an IMRT QA phantom (CIRS model 002H9K, 30 cm× 20 cm oval 
shaped) in order to confirm the asymmetry. The in-phantom doses were then 
measured inside a Rando pelvic phantom by placing TLDs along the AP and Lat 
central axis; from skin to skin (therefore skin doses were also measured). The 
absorbed dose was determined using the data provided in (Ma, Coffey, et al. 
2001). The skin and in-phantom doses were also measured for phantoms under 
the central-axis setup in order to check the difference to the table-drop setup. 
Calculation of skin and in-phantom doses were described in sections 3.4 and 3.5, 
respectively. 
2.2.3 The x-ray beam quality K 
 For kV x-rays, the first half value layer (HVL) and kV parameters were 
used to specify the beam quality. The experimental setup for HVL measurement 
is shown in Fig. 3. Measurement was performed under the radiographic mode of 
OBI using a technical setting of 125 kV, 80 mA and 160 ms with a half bowtie. 
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High-purity (99.9%) Al attenuators were used. The Al attenuator was placed 50 
cm away from a parallel-plate ion chamber (Keithly model 96035) and the x-ray 
collimators (blades or diaphragms) were set to 2 cm × 2 cm to make a narrow 
beam measurement.  
 The measured HVL at the central axis for a half bowtie was found to be 
6.3 mm Al. For the OBI, the collimators (blades) were installed only 20 cm from 
the source, different from the 50 cm specification in TG61 for therapeutic KV 
devices. However, as long as a narrow beam was used, the default collimation 
setup with OBI should be acceptable.  
 It is worth noting that the beam near the lateral edge can be harder than at 
the center because of the higher attenuation by the half bowtie filter. Also, the 
beam spectrum near the superior/inferior beam edge is somewhat different from 
that at beam center (Bhat, et al. 1999). We ignore these differences in this study. 
 
 
Figure 2: Dose distributions along the AP and Lat central-axis in the Rando pelvic phantom for (a) 
the central-axis (CA) and (b) the table-drop (TD) setups. The thin ring artifacts around the central-
axis in (a) were moved 3cm anterior in (b). 
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Figure 3: The experimental setup for HVL measurement. 
 
2.2.4 The skin (surface) dose measurement 
 TLDs were used previously for the entrance surface dose (Omrane, et al. 
2003) and the backscatter factor (BSF) (Coudin and and Marinello 1998) 
measurement of kV beams. In this study, LiF TLDs were calibrated against the 
Keithley parallel-plate ion chamber (model 96035) under the 125 kV x-rays with 
half-fan bowtie. First, the dose from KV beam was measured using the ion 
chamber. Then TLDs of the same batch were indexed and placed around the 
circle of the cylindrical sensitive volume on the surface of the parallel chamber. 
The sensitivity of each individual TLD was the ratio of the TLD reading to the 
average reading of all TLDs. Then TLDs having similar sensitivities were grouped 
and placed in capsules for skin dose measurement. The parallel-plate ion 
chamber was calibrated in an accredited dosimetry calibration laboratory (ADCL) 
using a 120 kV, HVL-4.15 mm Al beam and the air-kerma calibration factor Nk = 
2.08×106Gy/C. The chamber’s energy response varies <4% in a broad energy 
range of 20-150 KV. 
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 The dose on patient’s skin can be derived as: 
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Where M is the free-in-air parallel chamber reading after the temperature, 
pressure, polarity, ion-recombination and electrometer corrections; RTLD-Cali is the 
TLD reading from the calibration and RTLD is the TLD reading from the skin dose 
measurement; and RBG is the background reading of TLD. skinairen )/( ρµ  is the ratio 
of mass energy absorption coefficient of skin to air, averaged in free-air medium 
and it can be quoted from (Ma et al 1999, Table 2). Note that TLD’s over 
response (~15-20%) to KV x-rays was not involved here because the effect was 
cancelled. In this study, skin doses for 7 prostate patients were measured and 
multiple measurements were made for each patient.  Both the average dose and 
percent standard deviation (%SD) were calculated for each patient. As noted 
before, patient’s skin dose was only measured under the table-drop (3cm) setup.  
 Similarly, the surface dose on phantoms can be derived as 
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 The IMRT QA phantom is manufactured from proprietary materials that 
fully mimic water with 1% accuracy from 50 KeV to 50 MeV and therefore 
water
airen )/( ρµ  was used. The Rando phantom’s soft tissue was made of a 
proprietary urethane formulation with an effective atomic number and mass 
density that closely simulates muscle tissue with randomly distributed fat. The 
muscle
airen )/( ρµ  was used for dose calculation. Note that the surface dose is 
contributed by both the incident and transmitted projections. The effect of beam 
hardening for transmitted x-rays can be neglected because muscleairen )/( ρµ  in free-air 
varies <2% for all beams with HVL<10.0 mmAl. For the 30.2cmx12.0cm half-fan 
projection (366 cm2), the  muscleairen )/( ρµ ratio is only 0.2% less than the standard 
10cm x 10cm data (Ma et al 1999, Fig. 6). The surface doses were measured 
seven times for the IMRT QA phantom and four times for the Rando phantom. 
Measurements were made for both the table-drop (3cm) and central-axis setups.  
2.2.5 The in-phantom dose measurement 
 The in-phantom doses were measured inside the Rando pelvic phantom 
using TLDs. The slab at which TLDs were placed has both bone and muscle-
equivalent materials. TLDs were placed along the AP and Lat central-axis lines, 
as shown in Fig. 2(a) for central-axis setup and (b) for table-drop setup. One TLD 
per location and 4 measurements were made for each setup for improved dose 
statistics. Two or three TLD cubes were placed inside the femoral head to 
measure the dose to bone. Individual TLD’s response was documented. 
Measurements were made for both the table-drop (3cm) and central-axis setups. 
19 
 
 
 
 The in-phantom doses can be derived similarly as for Eq. (1), but the 
)/( ρµen  ratio was in muscle (or bone media) but not in air. The absorbed dose 
inside the tissue-equivalent material is 
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The TLDairen )/( ρµ  in free-air and in muscle (water equivalent) cannot cancel each 
other.  However, the waterairen )/( ρµ  in air and in water is less than 2% per TG-61 
and (Ma 1999, Table 2 & 3). Taking this ~2% difference for TLD which is nearly 
water equivalent at 125KV, the final dose calculation can be simplified to  
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We used the muscleairen )/( ρµ  averaged in free-air and in water media for calculation. 
Similarly, the absorbed dose inside bone was  
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where waterairen
bone
wateren
bone
airen )/()/()/( ρµρµρµ = . From (Ma et al 1999, Tables 2 & 3),   
bone
wateren )/ ρµ in free-air and in water for 6.3mm HVL beam can be ~5% different by 
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interpolating the data of 4.76 and 9.17 mmAl HVL. Again the average boneairen )/( ρµ  
in free-air and in water media was used for calculation. Also the beam quality at 
any TLD location can be different from that used for TLD calibration in air. Based 
on (Ma et al 1999), the bonewateren )/( ρµ  at 15 cm depth of water was 0.93 for 100 KV 
and 0.99 for 150 KV. We assume that for 125 KV, the ratio can be 0.96. The 
)/( ρµen bone to water ratio does not depend on SSD but field size. For the half-
fan field size of 12 cm x 30.2 cm, the bonewateren )/( ρµ  is ~2% higher than that of the 
standard 10cm x 10cm field.  
 KV dose measurements (using MOSFET detectors) inside a phantom 
consisting of soft tissue, bone and lung equivalent materials were reported before 
(Jones, et al. 2005). Based on the study, dose calculation inside bones using the 
free in-air boneairen )/( ρµ  provides ~±10% accuracy (based on the error bars) 
comparing to the Monte-Carlo simulation. Considering TLDs have less energy 
response than MOSFET, we expect the inaccuracy of bone dose calculation due 
to the approximation in Eq. (5) was better than 10%.  
2.3 Results 
2.3.1 Skin dose on patients (table-drop setup) 
 
           Table 1 showes the average skin doses and the percent standard 
deviations (%SD) at AP, Rt Lat and Lt Lat for patients of different sizes. The 
number of measurements (trials) was also given for each patient. AP dose 
strongly depends on patient’s separation, ranging from 3.2 cGy for 32.7 cm to 6.1 
cGy for 20.5 cm. Lat doses had little dependence on patient’s separation. Rt Lat 
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dose was 2-3 cGy, which was lower than the Lt Lat dose of 3.5-4 cGy by about 
~40%.  The standard deviations range from 3.5% to 17% for all data. 
 The fact that large patients received less AP doses is because of less 
transmission from posterior and posterior oblique projections, despite that large 
patients actually received higher skin doses from anterior and anterior oblique 
projections (because of the shorter source to skin distances, or SSD). For the 
three patients with AP separations 23.74 cm, 25.46 cm and 27.18 cm, AP doses 
were actually increased a few percent with increased separation. This means 
that the increased entrance doses from anterior projections outweigh the 
decreased transmission from posterior projections. For very thin (<22 cm) 
patients, the increased transmission outweigh the decreased entrance dose. 
Table 1. AP and Lat skin doses for patients (Table drop setup) 
 
Patient 
Total     
Trials 
TLDs     
Each 
Trial 
Patient Separation AP Dose Rt Lat Dose Lt Lat Dose 
AP          
(cm) 
Lateral          
(cm) 
Averag
e (cGy) 
%SD 
 
Average  
(cGy) 
%SD 
 
Average  
(cGy) 
%SD 
 
A 4 20 32.65 40.24 3.22 5.51% 2.68 8.75% 3.94 9.10% 
B 5 20 27.18 40.07 4.54 7.75% 2.55 11.27% 4.12 8.52% 
C 3 20 25.46 38.56 4.29 6.77% 2.54 6.23% N/A 
D 5 20 23.74 37.28 4.10 8.73% 2.39 3.46% 3.49 6.25% 
E 6 20 22.77 34.91 5.05 8.93% 2.51 5.95% 4.25 3.77% 
F 6 20 21.7 36.04 6.02 3.78% 2.34 7.06% N/A 
G 7 20 20.48 34.16 6.06 10.82% 2.78 16.78% N/A 
 
2.3.2 Surface dose on phantom 
 
 Table 2 first showed the surface doses and percent standard deviations 
(%SD) at the same three sites on the IMRT QA phantom for both the central-axis 
(CA) and table-drop (TD) setups. For this exactly symmetrical phantom, Lt Lat 
doses were measured to be ~40-50% higher than the Rt Lat doses. Comparing 
the table drop setup to the central-axis setup, AP dose was increased a few 
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percent but Lt Lat and Rt Lat doses were each decreased by a few percent.  The 
surface doses on the Rando pelvic phantom at the same three sites were also 
measured (at the time for in-phantom dose measurement) and shown on the 
second row of Table 2. With table-drop, AP dose is also increased in this case 
(may because that more side projections become incident rather than transmitted, 
which offset the dose decrement from the larger anterior SSD) but the Lt Lat and 
Rt Lat doses changes little. 
Table 2: Phantom surface doses from the central-axis (CA) and table-drop (TD) setups 
 
Phantom Num. trials 
TLDs     
per 
trial 
Sep. (cm) CA (SAD=100cm) (cGy) TD (SAD=103cm) (cGy) 
AP Lat 
AP Lt Lat Rt Lat AP Lt Lat Rt Lat 
Ave %SD Ave %SD Ave %SD Ave %SD Ave %SD Ave %SD 
IMRT 7 25 20 30 4.73 5.71% 4.52 4.23% 3.00 5.35% 5.12 4.31% 4.13 2.89% 2.77 2.92% 
Rando 4 25 20 33 4.91 4.83% 4.21 3.65% 2.61 3.47% 5.73 3.89% 4.30 4.03% 2.83 3.66% 
 
2.3.3 In-phantom dose in phantom 
 
 The in-phantom doses measured inside the Rando pelvic phantom using 
TLDs, along the AP and Lat central-axis (tattoo) were shown in Fig. 2 for (a) the 
central-axis and (b) the table-drop setups. The results were the average of all 4 
measurements for each setup. Again, the tissue and bone doses on the left side 
were higher than those on the right side. The anterior part of the phantom also 
received higher doses with table drop than with the central-axis setup. Doses at 
the AP, PA and Lt Lat peripheral area (except at the Rt Lat where the dose is 
about the same as the central dose ~3 cGy.) were ~40-50% higher than at the 
central.  The left femoral bone received the highest doses of 10-11 cGy while the 
right one received ~6-7 cGy.   
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2.4 Discussion 
 More measurements were made later in half-fan or full-fan scan, with or 
without bowtie, central-axis or table drop setup and all confirmed that the Lt Lat 
dose was higher than the Rt Lat dose. This dose asymmetry was found due to: (1) 
KV source always starts from Lt Lat and ends at Lt Lat. Gantry rotation get much 
slower near the end but dose rate stays constant; and (2) 10 deg scan overlap on 
the Lt Lat side (start and end). In-phantom dose measurement also confirmed 
that the peripheral dose at AP, PA and Lt Lat is higher than the central dose by 
about ~40%. The Rt Lat dose is about the same as the central dose.  
The normal tissue integral dose for a total of 42 fractions is in the range of 
~130 (central) to 200 (skin) cGy. Despite this dose is only ~2% of the prescription 
dose; it is, however, distributed over the whole scanned volume. Particularly, 
dose at the left femoral head can be up to 11 cGy per scan and the total dose 
can be more than 400 cGy from the whole treatment course. Adding this dose to 
the femoral dose received from treatment beams, which is ~3400 cGy in our 
institution, the total dose is still under tolerance (beam quality at 125 KV is close 
to that at MV.) However, the advantage of CBCT guided RT versus the 
disadvantage of additional KV dose may need further investigation, especially if 
low KV is used in the future. On the other hand, it is not too difficult to consider 
the CBCT dose as part of the prescription dose. Previously a model-based 
treatment planning system was developed for dose computations in the KV 
energy range using ADAC’s Pinnacle system (Alaei, Gerbi and Geise, Evaluation 
of a model-based treatment planning system for dose computations in the 
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kilovoltage energy range, 2000). It used the Monte Carlo technique to generate 
photon energy deposition kernels (Alaei, Gerbi and Geise, Generation and use of 
photon energy deposition kernels for diagnostic quality x-rays, 1999). The system 
was already applied for lung dose calculation at KV x-rays (Alaei, Gerbi and 
Geise, Lung dose calculations at kilovoltage x-ray energies using a model-based 
treatment planning system, 2001) and it could be used for the calculation of KV 
dose from CBCT. 
 The current Varian’s CBCT used a total of 1320 mAs (660 projections, 2 
mAs per projection, 125 KV). Compared to the total 660 mAs (330 projections) 
used in Synergy system at 120 KV, Varian’s CBCT delivers approximately 
doubled dose. For Synergy system (Islam 2006), the doses at the center and the 
surface for a cylindrical phantom of 30 cm diameter were 1.6 cGy and 2.3 cGy, 
respectively, which were about half of our measurement. Also, the lateral dose 
asymmetry was not reported for the Synergy system. By evaluating the image 
quality versus the number of projections for clinical needs, the number of 
projections for Varian’s CBCT may be reduced as well despite that the current 
CBCT used fixed projection number and technical settings. Some dose reduction 
strategies as discussed in (Islam, et al. 2006) could also be used for Varian’s 
CBCT. 
2.5 Conclusion 
 Absolute dose measurements have been made for pelvic CBCT scans 
with fixed technical and collimation settings using TLDs. These include skin 
doses for real patients and surface in-phantom doses for phantom. There were 
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two major findings from the measurements: (1). the lateral dose distribution is not 
symmetrical, with Lt Lat being ~40% higher than Rt Lat and (2). AP skin dose 
varies with patient size, ranging 3.2-6.1 cGy for patient’s AP separation of 20-33 
cm (the larger the separation, the less the skin dose) but lateral skin doses 
depend little on separations (Lt Lat dose was ~4.2 cGy and Rt Lat dose was ~2.6 
cGy in average). The in-phantom peripheral doses at AP, PA and Lt Lat areas 
were higher than the central dose (~3cGy) by about ~40% but the Rt Lat dose 
was about the same as the central dose. The highest in-phantom dose was 
inside the left femoral head (neck/hip joint region) where the maximum dose can 
be up to 11 cGy. The CBCT dose delivered to pelvic site for a total of 42 fractions 
can range from ~130 cGy to the central tissue, ~200 cGy to most of the 
peripheral tissues, and more than ~400 cGy to the left femoral bone. Varian 
released a new OBI version 1.4, which promised to reduce the CBCT dose. 
Several studies have been done to measure the absorbed dose from CBCT 
(Palm, et al. 2010) (Ding, et al. 2008). The CBCT dose is significant lower in the 
default CBCT modes with OBI 1.4 for pelvic scan (pelvis or pelvis spot light). 
However, the image quality and spatial resolution has been compromised to 
lower the dose.Varian released a new OBI version 1.4, which promised to reduce 
the CBCT dose. Several studies have been done to measure or use Monte Carlo 
simulaton to calculate the absorbed dose from CBCT (Palm, et al. 2010) (Ding, et 
al. 2008). The CBCT dose is in OBI 1.4 can be reduced to one-fifth of the dose 
received with OBI 1.3 for head and neck region while the dose can be halved in 
the pelvic scan. The default CBCT modes in OBI 1.4 for pelvic scan are pelvis 
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spot light (125kV, 80mA, 25ms) and pelvis (125kV, 80mA, 13ms). The pelvis spot 
light acquires CBCT images in 200 degrees acquisition angles instead of 360 
degrees. CBCT dose in the pelvis mode is reduced due to lower mAs. The image 
quality and spatial resolution has been compromised to lower the dose in OBI 1.4.  
The advantage of CBCT guided RT versus the disadvantage of additional KV 
dose worth to be further investigated. 
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CHAPTER 3: ADAPTIVE RADIATION THERAPY 
3.1 Introduction 
 Radiation beam can be controlled and shaped to the TV precisely under 
the development of modern linear accelerator and MLC. The advancement of 
IMRT allows modulating the intensity of the beam to further improve the dose 
conformality to the target and to minimize the dose to surrounding critical organs.  
 However, the level of precision achieved in the plan may not be applied to 
the real world. The intra- and inter- fraction motion can potentially negate the 
merit of IMRT. The expansion from clinical target volume (CTV) to planning 
target volume (PTV) accounts for internal organ motion and setup errors. The 
method significantly compromises the effectiveness of IMRT. IGRT is emerging 
by using different imaging modalities to assess the real time patient geometry 
and applying shift to match planning position. CBCT is one of the imaging tools to 
provide online patient setup information to correct for inter-fraction motion. The 
online matching algorithm used in KV CBCT system is rigid body registration 
which has six degrees of freedom (three translational and three rotational).  The 
online table correction can be done either 4D (Exact couch) or 6D (robotic couch) 
based on the registration results. However, the studies have shown that the 
position and shape of the TV and OAR vary between the simulation and 
treatment, which may have consequences of impacting tumor control and normal 
tissue complication probability (Pollack, et al. 2002) (Roeske and al. 1995) 
(Beard, et al. 1996) (Tinger, et al. 1998) (Dawson, et al. 1998) (Zelefsky, Crean, 
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et al. 1999). Such anatomy deformations are also observed in our daily clinical 
practices which bring difficulty to apply IGRT effectively (Fig.4). 
 
Figure 4: Anatomy deformation is shown between SIM-CT (left upper corner) and three treatment 
sessions. Rectal gas increases the rectal volume and causes the movement and deformation of 
prostate. 
 
 The patient anatomy and positioning information obtained from CBCT 
allow us to assess the anatomy deformation and dosimetric implications and 
make corrections during the course of treatment. With 3D volume information, 
CBCT offers the opportunity to elevate radiotherapy to the next level – ART.  
 ART is a closed-loop feedback algorithm which evaluates the organ 
deformation and motion right before the treatment and takes into account dose 
delivery variation daily to compensate the difference between planned and 
delivered dose. It also has a potential to allow further dose escalation and margin 
reduction to improve the clinical outcome. A serious of studies has shown that 
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dose escalation can improve the outcome of treatment of prostate cancer 
(Zelefsky, Leibel, et al. 1998) (Pollack, et al. 2002) (Peeters, et al. 2006) 
(Martinez, et al. 2005). ART is the promising strategy to optimize the delivered 
dose distribution to both the target and OAR. 
3.2 Materials and Methods 
3.2.1 Image-Guided Radiation Treatment of prostate cancer 
 
An institutional review board (IRB) approved protocol has been 
established at Henry Ford Hospital to evaluate various IGRT modalities in 
prostate cancer treatment. All the patients enrolled in the protocol were instructed 
for the bladder and bowel preparation. The patient position and rectum/bladder 
filling were assessed during the CT simulation by acquiring a short length helical 
CT scan. The full bladder and empty rectum without gas were required for 
planning purpose. The patients were simulated in 3 mm slice thickness with 
Brilliance CT 16-slice (Philips Medical Systems, the Nederland).  No Intravenous 
or oral contrast was given to the patient. The technical settings of the pelvis 
protocol were 120kV, 500mAs. The prescription dose for most patients was 
75.6Gy (1.8Gy x 42 fractions). If the patient was also under the IRB gene therapy 
protocol then 80Gy (2Gy x 40 fractions) was prescribed based on the criteria of 
the protocol. The CTV included prostate and 1cm proximal seminal vesicles 
which were defined as the geometrical intersection of seminal vesicles with 
prostate expanded by 1cm margin. PTV was created by adding 1cm margin to 
CTV except 6mm posteriorly to limit rectal dose. The treatment plans were 7 to 9 
fields IMRT (Fig.5.).  
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There is a normal tissue dose constraint criteria used at Henry Ford 
Hospital for treatment planning. This criterion matches the normal tissue 
dose/volume tolerance guidelines published recently by the Quantitative Analysis 
of Normal Tissue Effects in the Clinic (QUANTEC, Lawrence, et al. 2010).  The 
comparisons of the two guidelines for rectum and bladder are listed in table 3. All 
the treatment plans optimized under Henry Ford criteria are also evaluated to 
comply with the QUANTEC guideline.  
 Table 3: OAR constraints criteria for prostate cancer treatment 
 
 Volume 10% 15% 20% 25% 30% 35% 40% 50% 60% 
HF 
Criteria 
Rectum 75 - 70 - 65 - 60 - 40 
Bladder 80 - 75 - 70 - 65 - 45 
Quantec Rectum - 75 70 65 - 60 - 50 - 
Bladder - 80 - 75 - 70 - 65 - 
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Figure 5: 9-fields IMRT treatment plan of prostate cancer. 
 CBCT was acquired before each treatment for online image guidance. The 
rigid registration was performed online to fuse CBCT to SIM-CT. After the scan 
was completed, SIM-CT and CBCT were further processed in the 3D/3D match 
workspace for the co-registration and anatomy evaluation. The CBCT images 
were evaluated first. If the bladder or rectum fillings were not satisfactory for the 
treatment, the patients were taken off the treatment couch and instructed to drink 
more water, void the bladder and rectum or otherwise achieve better condition. 
After the patient has followed the instructions, he would be re-positioned on the 
treatment couch and another CBCT was re-acquired. The final CBCT and SIM-
CT image data sets were then matched using automatic image registration 
algorithm with four degrees of freedom as shown in Fig.6 (three translations and 
one couch rotation). If the auto registration did not match the images well, the 
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registration could be adjusted by manual matching. The patient position was 
corrected in three translational directions based on registration results.  
 
Figure 6: Online 3D-3D rigid image registration of SIM-CT and CBCT. 
Five patients were selected to be processed retrospectively for this ART 
study. The maximum CBCT longitudinal scan range was about 20cm when 
source to detector distance was 150cm which was the standard clinical setting. 
However, the reconstructed 3D information was shorter due to the loss of 
information at the peripheral region. If the lymph node was involved in the 
treatment, CBCT could not cover all the treatment area. Therefore, there was not 
enough information to reconstruct the dose and re-optimize the calculation. Only 
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low risk patients with localized prostate cancer were selected for the study (table 
4). The risk classification was defined as following: 
Low risk: prostate cancers are unlikely to grow or spread for many years 
 PSA<10ng/ml 
 Gleason score <=6 
 Stage:  T1 and T2a 
Intermediate risk: cancers are unlikely to grow or spread for a few years 
 PSA is between 10 and 20 ng/ml 
 Gleason score is 7 
 Stage:  T2b and T2c 
High risk: cancers may grow or spread within a few years 
 PSA >20 ng/ml 
 Gleason score is 8 - 10 
 Stage:  T3 and T4 
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Table 4: The patients’ prognostic factors and treatment plan parameters 
 
Patient 1 2 3 4 5 
Age 65 78 64 78 61 
CTV (cc) 
(Prostate+1cm Prox SV)  
63.27 51.2 32.19 69.64 48.23 
PTV definition 1cm around 
6mm 
posterior 
1cm around 
4mm 
posterior 
1cm around 
6mm 
posterior 
1cm around 
6mm 
posterior 
1cm around 
6mm 
posterior 
PSA (ng/ml) 3.3 5 3.23 7.9 5 
Gleason Score 6 7 6 6 6 
T stage T1c T2 T1c T2 T1c 
Dose Fraction 42 40 42 40 42 
Prescription  Dose (Gy) 75.6 80 75.6 80 75.6 
 
3.2.2 CBCT based dose calculation 
 
3.2.2.1 HU (hounsfield unit) number – relative ED (electron density) calibration 
 CBCT has great potential to be used for the ART better than other image 
modalities since it has the quantitative advantage as CT images and volumetric 
information of patient online position. However, scatter and artifacts in the current 
CBCT images degrades its application in target delineation and dose calculation. 
The dose calculation accuracy needs to be carefully evaluated before its 
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implementation in ART. Several studies have demonstrated the feasibility of 
using CBCT for dose calculation (Ding, et al. 2007) (Yoo and Yin 2006). Since 
the accuracy of CBCT based dose calculation is vital for ART, the dosimetric 
feasibility of CBCT was re-evaluated. 
 The scatter contribution of CBCT was proportional to scan volume. Guan 
(Guan and Dong 2009) recommended the HU-ED calibration should be done for 
each scanning mode. Since the study only focused on ART of localized prostate 
cancer patients with same CBCT scanning parameters, the ED-HU calibration 
was evaluated for the pelvis setting only. In the pelvis mode, the technical setting 
of CBCT was 125 kV, 80mA, 13ms and the scan was performed in half fan mode 
with half bow-tie mounted. The blade size Y was set to 12cm symmetrically for all 
patients.   
 The Catphan 500 (The Phantom Laboratory, Salem, NY) is the standard 
phantom for CBCT calibration. It has five different modules for CT QA. CTP404 
module consists of seven high contrast sensitometric targets which are made 
from Teflon®, delrin®, acrylic, polystyrene, water, low density polyethylene, PMP 
and air. The CT numbers for these targets range from -1000 to 1000. The 
phantom and one axial slice of the phantom are shown in Fig. 7. The phantom 
was scanned in both SIM-CT and CBCT under the standard clinical settings for 
the pelvic site. HU for each target was measured by averaging the value of 10 
points surrounding the center of the target (Fig.7).  
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Figure 7: (a) Catphan 500. The diameter and length of the phantom are both 20cm. (b) The SIM-CT 
axial slice and (c) the CBCT axial slice of Caphan which show eight targets for HU-ED calibration. 
 
3.2.2.2 Dose calculation evaluation – phantom & patient study 
 The Rando Pelvic phantom was used to evaluate the accuracy of dose 
calculation of CBCT. The Rando phantom was scanned in both SIM-CT and 
CBCT and the two image sets were co-registered in Eclipse. The structures were 
drawn to represent prostate, bladder and rectum in SIM-CT and copied to CBCT. 
There was minor difference (< 1%) of the volumes in the two image sets due to 
interpolation since the pixel matrix is different between SIM-CT (512x512) and 
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CBCT (384x384). The treatment plan was calculated using 6MV beam in the 
Eclipse treatment planning system with pencil beam algorithm. There were three 
different treatment plans used for the evaluation, 4-fields box with / without 
inhomogeneity correction and 9 fields IMRT. 4-fields box was the 3D plan to treat 
pelvis using AP, PA, Lt Lat, and Rt Lat beams. It provided a relatively high dose 
box at the intersection of the beams where the lesions were located.  The 9-fields 
IMRT plan was generated from the standard template used for the prostate 
cancer treatment at Henry Ford Hospital. The gantry angles were 200°, 240°, 
280°, 320°, 0°, 40°, 80°, 120°, and 160° respectively. The optimization was 
based on the same criteria (table 7). Modified Batho method was used for the 
inhomogeneity correction.  All three plans were generated in the SIM-CT and 
copied to the CBCT to recalculate with same beam parameters.  
 Same method was applied to study the dose calculation accuracy for 
patients. One CBCT image set of a patient with minimum organ deformation 
compared to SIM-CT was chosen for evaluation. The CBCT image was 
registered rigidly to the SIM-CT in Eclipse. All the structures were duplicated to 
the CBCT image set. The original plan used for the patient treatment was copied 
and re-calculated on the CBCT image set.  
3.2.3 Deformable Image Registration (DIR) 
 The image uses voxels to sample a continuous field. Each voxel is 
monochromatic and has same size in any particular image. Each voxel has x, y 
and z dimension and intensity associated with it. The finer the voxel is, the more 
accurately it represents the original image. The greater the bit depth is, the better 
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the contrast resolution. All the voxels are indexed in the image grid (Fig.8). Image 
registration transforms the points in one image to the corresponding points in the 
other image. However, such transformation cannot be converted from one image 
grid to the other image grid directly. It needs to be transformed in the physical 
coordinate and converted back to the image grid (Fig.9). The voxel physical 
coordinate along each direction is defined as 
   
sizenIndexOriginnV ×+= ][][     (6) 
 
 
Figure 8: The grid samples the continuous image. All the voxels laid on the grid are indexed. The 
typical voxel matrix in the CT image is 512 x 512 x 3 and the bit depth is 16 bits. The voxels are 
indexed in all three dimensions. The voxel sizes in x and y dimension are calculated by field of 
view/matrix size and the voxel size in z dimension is equal to slice thickness. 
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Figure 9: The image registration cannot be performed on the image grid directly. The physical 
coordinates of the pixels in the fixed image are calculated based on the image origin, pixel index and 
size. The pixels are transformed from physical space of fixed image to that of moving image. Then 
the moving image is resampled. 
  
 There are two different objects in the image registration, fixed image and 
moving image. The moving image is the one to be re-sampled back to the fixed 
image grid. Denomination of the fixed/moving image is arbitrary. However, since 
CBCT contains the patient anatomy information at the treatment position, doses 
should be calculated on CBCT and warped back to SIM-CT for post processing 
and composite dose summation. Because doses are reconstructed in the 
opposite direction of the vector fields that define the mapping from the fixed 
image to the moving image, the fixed image should be SIM-CT and the moving 
image should be CBCT acquired from each treatment session. The correct image 
voxel size and origin is vital for registration since it is done in the physical 
coordinates. The comparison of image coordinate between CBCT and SIM-CT is 
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listed in table 5. All the DICOM images are converted into 3D raw data for the 
registration. The header of the raw data should specify image coordinate and bit 
depth information in order to register accurately in the physical coordinates.  
 The purpose of image registration is to maximize the similarity metrics 
between the fixed image and the moving image through transformation. Rigid 
registration only allows 6-degrees of freedom of transformation. All the voxels 
move along the same direction with the same quantity. It is not sufficient for 
accurate registration which can account for organ deformation. DIR provides 
displacement vector field (DVF) which defines the voxel to voxel mapping 
between the fixed image and the moving image.  There are several steps to 
perform DIR (Klein and Staring 2008). Image metrics measures similarity 
distance between images. Optimizer aligns the images as good as possible 
based on the measures. Then the moving image is transformed toward the fixed 
image based on the optimization result (Fig.10).  
 
Table 5: Example of image coordinates of SIM-CT vs. CBCT 
 
 SIM-CT CBCT 
Origin (mm) -275, -614, 128.383 -449.414, -449.414, -79.5 
Element Spacing (mm) 1.074, 1.074, 3 1.172, 1.172, 3 
Dimension Size 512, 512, 75 384, 384, 53 
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Figure 10: DIR includes similarity measure, optimization, transformation and interpolation.   
 
3.2.3.1 Image Metrics 
 Either point based or intensity based method is used for similarity 
measures (Xing L 2007). Point based methods minimize the difference of the 
points on the surface of anatomical structure. A large amount of landmarks need 
to be selected to achieve good representation which takes lots of manpower. 
Intensity based method measures the voxel intensity difference directly which is 
accurate, fast and less human interaction needed. There are several different 
similarity measurers available in ITK: sum of square (SSD), mean of square (MS), 
and mutual information (MI) etc (Luis, et al. 2005).  
• Sum of square 
 SSD is the sum of squared intensity difference. N is number of pixels. Fi is 
the ith pixel in the fixed image and Mi is the ith pixel in the moving image. SSD is 
only applicable in single modality registration since it is very sensitive to large 
intensity difference.  
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• Mean of square 
 MS is the mean squared pixel intensity difference between the fixed image 
and the moving image.  
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• Mutual Information 
 MI measures the correlation of image intensity from the fixed image to the 
moving image. It is computed based on the entropy. The entropy is the very 
important concept in thermodynamics which describes the disorder in a system. 
In information theory, the entropy represents the amount of information in one 
image to reduce the uncertainty in the other image. The entropy in the fixed 
image is described as 
    diipipS FFF )(log)( 2∫−=     (9) 
The entropy in the moving image is described as  
    djjpjpS MMM )(log)( 2∫−=      (10) 
The joint entropy of the fixed image and the moving image is described as 
    didjjipjipS MFMFMF ),(log),( ,2,, ∫−=   (11) 
Where pM and pF is the marginal probability density functions of the fixed  image 
and moving image respectively. pF,M is the joint probability density function 
between the two images. The MI is defined as the difference of the entropy  
    MI = S! + S! − S!,!      (12) 
Combine equation 9-12, MI is calculated by 
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MI has become the standard DIR, especially in multi-modality registration (Pluim 
and Maintz 2003). MI was used to evaluate intensity metrics between SIM-CT 
and CBCT in my work for DIR. 
3.2.3.2 Optimizer 
 Optimization algorithm has various applications. In the image registration, 
the optimizer optimizes the transformation parameters to minimize the cost 
function which is the similarity metrics. There are two types of optimizers in ITK, 
single valued optimizer and multiple valued optimizer. The single valued 
optimizer is suitable for the cost function of image registration which returns a 
single value. Gradient descent (GD) and Robbins-Monro (RM) are both single 
value optimizers to obtain optimal transformation parameter.  
• Gradient descent 
 The optimization starts at a zero shift position of two image sets. The 
direction for the next step is set as the negative gradient of the cost function 
(Fig.11). The next position will be  
     x’=x-h*f’(x)     (14) 
 
where x is the current position, x’ is the next position, h is step size and f(x) is the 
cost function. The step size is crucial to tune the optimization. If the value is too 
high, the image may be deformed beyond recognition. If the value is too low, the 
optimum may not be reached. The local minimum can be avoided with 
appropriate value of step size.  
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Figure 11: The optimization starts at the initial position. The direction of the descent is the negative 
derivative of the cost function. The new position is updated at each iteration based on the step size.   
 
3.2.3.3 Transformation 
 There are many algorithms to determine the deformation between the 
fixed and moving images. ITK offers a variety of transforms. Two common ones 
are Demons and B-Spline.  
• Demons 
 The demons were first introduced by Maxwell in the 19th century to 
illustrate thermodynamics. Two different types of particles were separated by the 
membrane in a container. The demons existed in the membrane which allowed 
one type of particles to diffuse over but not the other type of particles. Thirion’s 
demons algorithm applies similar concept by diffusing the deformed image 
through the contour of the objects in the fixed image through demons (Thirion 
1998). The boundaries in the fixed image are considered as membrane. The 
deformed grid which represents the deformed image diffuses through the 
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interfaces. The deformed grid can be rigid or allow for more freedom depending 
on types of deformation. The force, derived from gradient information of the fixed 
image, deforms the moving image based on the intensity difference between the 
two image sets. At each voxel level, the force pushes the voxel in the moving 
image toward the fixed image. The deformation field is defined as  
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Where m and f are the external forces of the fixed and moving image respectively, 
f∇

is the gradient of the surrounding force. 
• B-Spline 
 B-Spline transformation generates deformation vector of every control 
point defined on a coarse grid which is the B-Spline grid. The B-Spline grid can 
be defined differently in each direction based on the dimension of the 3D image. 
The DVF is computed using B-Spline interpolation based on the existing 
deformation values on the grid. It is a local deformation method which means the 
transformation of a point can be computed from the surrounding points only. To 
compensate for the limitation, a rigid or affine transformation needs to be 
performed first. The deformation field is defined as  
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3.2.3.4 Interpolator 
During the optimization, the intensity value is compared in the fixed image 
against the corresponding value in the deformed image. Since the fixed image 
has different grid size compared to the moving image usually, the grid points are 
mapped to non-rigid positions in general. Interpolator is necessary to evaluate 
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the intensity value of these non-grid points on the moving image. There are 
several ways to do interpolation - linear interpolation or Nth order B-Spline. The 
higher order of the B-Spline function, the better quality is achieved but with more 
computation time. When N is one, B-Spline becomes linear interpolation.  
3.2.3.5 Multi-resolution 
 It is not necessary to select all voxels in the fixed image to calculate MI 
since it costs a lot of memory and time to calculate huge amounts of data. The 
multi-resolution approach can improve the registration speed, accuracy and 
robustness. A grid which down samples the fixed image is defined for each 
resolution level to generate MI. The sampling starts at a coarse level and is tuned 
at the next finer scale. The process can be repeated at multiple levels until it 
reaches the finest scale possible.  The multi-resolution strategy can reduce data 
and transformation complexity to get better and more flexible DIR (Lester and 
Arridge 1999).   
3.2.4 Evaluation on DIR 
 
 The difficult problem of DIR is to evaluate whether the registration is 
successful. The rigid registration is easy to verify based on the structures or 
some landmarks since all the voxels are shifted together toward the same 
direction. However, it is impossible to track where each voxel is mapped to 
visually. The evaluation of the DIR can be done quantitatively or qualitatively, 
such as checking the fiducial markers, comparing images side by side, and 
validating the registration with voxel level based algorithm.  
• Fiducial markers based validation 
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 Three Acculoc gold seed fiducial markers (Northwest Medical Physics 
Equipment, MEDTEC Company, Orange City, Iowa) are implanted in the prostate 
gland of patients enrolled in the IGRT protocol. The primary objective of the 
protocol is to compare the range of agreement of patient shifts given by each 
image modality, U/S. vs. in-room orthogonal KV images using fiducial markers vs. 
CBCT. One seed should be placed in the base of prostate on the left or right side. 
The second one should be placed toward the mid-prostate gland. The third one 
should be implanted toward the apex. The dimension of the markers is about 
1mm in diameter and 3mm in length. These seeds could be tracked to evaluate 
the accuracy of the registration. However, the drawback is that three markers are 
insufficient to validate the registration accuracy of the entire volume. 
• Image comparison side by side visually 
 The deformed image should be exactly same as the fixed image ideally. 
The two images can be overlaid on top of each other and checked by split view, 
chess view, blending view or spy glass. However, CBCT has relative poor quality 
due to larger scatter contribution. In prostate scan, the boundary between 
prostate and rectum is blurred and difficult to evaluate. Such comparison is also 
subjective based on the reviewer.  
• Unbalanced energy (UE) 
 The DVF accuracy is vital to achieve accurate dose reconstruction of 
deformed organ. For the low intensity region like prostate, the displacement 
variations are relatively insensitive to the similarity metrics which may result in 
DIR error. The poor image quality in the prostate region of CBCT also makes the 
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validation of registration difficult. Zhong proposed an automatic method using UE 
to quantify the DVF error (Zhong, Peters and Siebers 2007). 
 The method characterizes the organ deformation similar to the 
displacement and elastic force used in the solid continuum mechanics. The 
organ is simulated as an elastic body without any external forces acting inferiorly. 
At the equilibrium position, the work done by the external forces on the organ 
surface will be equal to the energy from the tissue deformation while internal 
forces at each node must be zero. The elastic force at each node contributing 
from the neighboring elements is defined as   
     !! = !!"!×!! = !!!!"! !!    (17) 
where Ke is the stiffness matrix of the elastic material, Ee is Young’s modulus of 
the element e, dj is the displacement factor of jth vertex and Fi is the external 
force to the node i. The unbalanced force at each vertex j is defined as  
     !! = !!!(!) + !!!(!)    (18) 
 The unbalanced force is due to two sources. One is inaccurate material E0 
which is the assigned initial Young’s modulus and the other is an unknown 
displacement factor approximated by DVF. The UE is the product of the 
unbalanced force and the DVF.   UE can be used to assess the registration 
performance based on its value. The lesser the value is, the better DIR is 
performed on the vertex. By assigning the value to the vertices of each element, 
the 3D UE images can be reconstructed to evaluate the DIR.    
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3.2.5 Dose Reconstruction and accumulation 
 The dose for each treatment fraction is recalculated on CBCT with exactly 
same treatment plan parameters (beam angle, MU, fluence and calculation 
algorithm etc.). The dose grid size is set to 0.25cm. Since the dose grid is not the 
same as the B-Spline grid, DVF cannot be applied to the dose grid directly. The 
CBCT dose is first warped back to the SIM-CT image grid with the direct 
approximation using the transformation matrix. The closest neighboring points on 
the SIM-CT image grid are estimated by the B-Spline interpolation. Then the 
warped dose on the SIM-CT is resampled to match the location on the planning 
dose grid with B-Spline interpolation method. Fig.12 shows the two steps for the 
dose reconstructions.  
Since all fraction doses warped from SIM-CT have the same grid size of 
the planning dose, the dose accumulation is performed by adding the dose value 
of each point on the dose grid. If the CBCT is not acquired during the treatment 
due to the OBI problem, single fraction planning dose is used to represent dose 
for the treatment session. 
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Figure 12: Dose reconstruction. (a) dose was recalculated on the CBCT after rigid registered with 
SIM-CT, (b) warp dose by applying the transformation matrix generated in DIR, (c) resample the 
warped dose from B-Spline grid to the dose grid. 
 
3.2.6 The Flow of ART 
 The ART can be described as a closed-loop control (Zerda, B and Xing 
2007). The conventional treatment planning 3D or IMRT is open-loop control. 
There is no feedback of the ongoing treatment to update patient’s anatomy 
information. For the closed-loop control, the treatment planning can be repeated 
as a loop with the feedback of CBCT to represent the updated patient geometry. 
The framework for ART is shown in Fig.13. The patient was treated with IMRT 
plan based on the SIM-CT. CBCT was acquired before each treatment for online 
setup. The patient was shifted based on the rigid registration result of CBCT and 
SIM-CT. Dose was recalculated on each CBCT with the same plan. The DIR was 
performed and evaluated offline and the DVF was generated accordingly. Dose 
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was reconstructed and accumulated to reflect the actual dose delivered to the 
patient. Then the adaptive plans at any fractions were compared to the original 
plan to evaluate the deviation of PTV coverage and OAR dose limit. If the actual 
dose delivered to PTV deviated clinically significant from the prescription dose for 
the given fractions, or if OAR received higher dose than expected, the treatment 
plan would be re-optimized based on the previously delivered dose.  The criteria 
to trigger re-optimization were clinical assessments. My study focused on the 
treatment planning outcome to come up with the feasible optimization schedule 
to achieve the balance of PTV dose coverage and inhomogeneity, OAR dose 
constraint and time involved.    
  
Figure 13: The flow chart of ART. The patients are treated with IGRT protocol. DIR and dose 
reconstruction are performed offline. The plan is evaluated and optimization necessity is considered.  
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With the ART applications, the systematic error for the prostate treatment 
should be reduced; therefore the smaller margin should be enough to account for 
all the setup errors, prostate motion and random errors. If it is valid, the ART not 
only compensates for dose deficiency due to organ deformation but also has 
significant benefits of reducing organ toxicity, which makes planning easier and 
PTV coverage more homogeneous and allow for further dose escalation. The 
study addressed such potential benefit of ART.  For each patient, two new IMRT 
plans were produced using the SIM-CT with a smaller margin applied to the CTV. 
The PTV margin for the original plan was 10mm around and 6mm posterior. The 
margin was reduced to 5mm around except 3mm posterior for one IMRT plan 
and 3mm all around for the other plan. The new plans were applied to each 
CBCT set and the adaptive procedures were repeated to generate actual dose 
delivered. The 5/3 mm margin was selected since it had been used by multiple 
clinical trials. The prostate intra-fraction motion was around 2-3mm based on the 
results of Calypso® protocol at Henry Ford Hospital (Fig.14). Considering all 
other uncertainties, such as image resolution, DIR registration accuracy, and 
dose reconstruction, 3 mm was at the lower end of the margin’s confidence level 
to account for the motion of the target. 
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Figure 14: Three calypso beacons were implanted toward the apex, the left base and the right base of 
the prostate gland. These beacons provided real time tracking during the treatment delivery. The 
detected radiation was shown as shaded area on the report. If the offset was larger than 5mm in one 
or more axes, the treatment was stopped immediately.   The prostate motion was very stable for most 
treatments where the offset was less than 2mm usually.  
 
3.2.7 Plan evaluation – Radiobiological Model 
 The treatment plan is evaluated routinely by utilizing the dose-volume 
histogram (DVH). DVH indicates the amount of volume of interest that receives a 
certain dose or higher. The dose value can be re-sampled into equi-spaced 
intervals. Then the volume of the voxels receiving dose within the interval is 
accumulated. The cumulative DVH is obtained by adding the voxels receiving a 
specified dose or more. However, even though DVH shows dose coverage of a 
volume, it does not contain any spatial information of the dose distribution. Cold 
spots in a small volume of tumor may not have noticeable impact on the DVH but 
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the tumor control can be diminished as a result. Therefore DVH can be a good 
supplement to isodose distribution in the plan evaluation, but not as a sole 
standard. Radiobiological model has been used to evaluate and predict the 
clinical outcome in terms of both a tumor control probability (TCP) and normal 
tissue complication probability (NTCP). The treatment plan can be ranked using 
the biological data, volumetric dose distribution and the DVH for different organs.   
3.2.7.1 TCP 
 TCP describes the probability of killing tumor clonogenic cells in the TV for 
a given dose. All TCP models have similar assumption that the lesion is killed if 
all clonogenic cells  are destroyed by radiation. The TCP in the study is poisson 
statistics-based model. The model assumes that dose response for tumor is 
sigmoidal in shape and the number of surviving clonogens follows poisson 
distribution coupled with Linear-Quadratic (LQ) model. The model is express as  
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Where Ni is the initial clonogenic cells density of the voxel i in the tumor, SFi(Di) 
is the surviving fraction of the voxel i at given prescription dose. The assumption 
is made that the clonogenic cells are evenly distributed across PTV. The 
common expression of surviving fraction calculated by the LQ model is  
     !" = !!(!"!!!!)    (20) 
 Where α represents the probability of double chromosome break which is 
irreparable and β represents the probability of single chromosome break which is 
reparable. If the fraction dose is not 2Gy, SF can be calculated biologically 
equivalent from SF2,  
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     SF = SF2D /2      (21) 
Where SF2 is the surviving fraction at 2Gy and D is the prescription dose.  
 In order to get tumor control data, patients need to have adequate follow-
up. There are different estimations of prostate TCP parameters (Webb 1994) 
(Webb and Nahum 1993) (Sanchez-Nieto and Nahum 1999).  The TCP model 
shows that SF2 and N0 are the dominant factors of radio-resistance in prostate 
cancer. SF2 ranges from 0.5 to 0.6 and N0 is about 104 – 107 cells/cm3. The α/β 
ratio tells the sensitivity of the tissue response to fractionation effects. Tumor α/β 
value is usually 10Gy since they are accutely responding tissues. Late effect 
usually occurs in slowly proliferating tissue such as bladder or rectum which has 
α/β ratios of 2.5-5 Gy and 3-7Gy respectively. However, it is now believed that 
the α/β value is much lower for prostate tumors. α/β value of prostate is 
estimated ranging from 1-5 Gy from a large multicenter database, such as the 
university of Michigan, Royal Brisbane Hospital, and the William Beaumont 
Hospital (Brenner, 2002) (Folwer and Ritter 2001)). Fowler et al. estimated α/β 
ratio for prostate cancer is about 1.5Gy which may be even lower than the 
surrounding late responding normal tissue (Fowler and Ritter 2003).  
3.2.7.2 NTCP 
 NTCP model describes the probability of unfavorable reactions in normal 
tissue responding to radiation. Four parameter LKB-NTCP model was fit to 
normal tissue tolerance data (Emami, et al. 1991) (Burman, Kutcher and Emami 
1991). The model assesses the possibility that complication will occur for a given 
dose no matter how small the partial volume is. The model is described as  
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Where TD50 is defined as dose received by the volume that could lead to a 
complication probability of 50 percent, Vref is the volume for TD50, m is the slope 
of the complication probability vs. dose curve, and n is the volume dependence 
of the complication probability. n differs the tolerance dose for partial and whole 
organ. When n is close to zero, the volume effect is small and when n is close to 
1, the volume effect is large. The organ with a smaller n indicates a serial organ 
and the one with a large n can be qualified as a parallel organ. If any portion of a 
serial organ receives the dose above the tolerance, it loses the complete 
functionality. If a large volume of a parallel organ receives the dose above the 
tolerance limit, it is considered damaged.  
 The model parameters are generated by curve fitting. Patients are 
followed up to evaluate genito-urinary (GU) and gastro-intestinal (GI) 
complication. The side effect of GI is diarrhea, rectal pain, rectal bleeding, rectal 
ulceration, and rectal fistula. The side effect of GU is incontinence, persistent 
urinary retention, increased urinary frequency/urgency, and urethral stricture. 
Emami et al (Emami and Lyman, 1991) provided tolerance dose for whole organ 
irradiation listed in table 6. However the data for volume dependence was not 
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sufficient. The tolerance data was only for one volume. There could be more 
uncertainty and less confidence for the fitted parameters. 
Table 6: NTCP parameters published by Emami 
Organ Vref TD50 n m End Point 
Rectum Whole Organ 80 0.12 0.15 Severe necrosis/fistula/stenosis/proctitis 
Bladder Whole Organ 80 0.5 0.11 Symptomatic bladder contracture/Volume loss 
 
 The quality and quantity of clinical data have begun to improve 
significantly in the last decade. Several other groups provided estimated 
parameters for the LKB model by fitting to the late GU/GI toxicity data. The GU 
parameters shown in table 7 were generated from 128 patients with prescription 
dose 78 Gy (Cheung, Tucker and Lei 2007). n was very close to zero which 
means the toxicity was directly related to the maximum dose to bladder. The 
Italian multi-centric study fitted the late rectal bleeding data using the NTCP 
model listed in table 7 (Rancati, Fiorino and Gagliardi 2004). It showed that the 
models fitted the complication very well in qualitative and quantitative 
comparisons. It also suggested that the rectum is a serial organ.  
     Table 7: NTCP model parameters fitted to the late GU/GI toxicity from other research groups 
Organ TD50 n m End Point 
Rectum 81.9 0.23 0.19 Grade2/3 late bleeding 
Rectum 78.6 0.06 0.06 Grade 3 late bleeding 
Bladder 77.6 0.00995 0.022 Grade >=1 late GU toxicity 
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3.2.8 Re-Optimization 
 The optimization must make a balance between sufficient tumor coverage 
and sparing OAR. There are generally two categories in the optimization 
algorithms: deterministic methods and stochastic methods. The deterministic 
methods include gradient descent and maximum likelihood. The stochastic 
methods include simulated annealing and genetic algorithms.  The optimization 
uses objectives functions in terms of dose-volume. The upper objective is used to 
limit the hotspot in the target and the dose in other OAR. The lower objective is 
used to define the dose level in the target to receive at least a specified dose for 
a certain percentage of volume. The objective function can be written in a 
weighted least square model  
     !" = !! (!!! (!)−!!!"#)!!!!!     (26) 
Where wk is the weight for organ k, !!!  is the dose at voxel i in organ k and  !!!"# is 
the objective dose constraint to the organ. The cross section of a beam is broken 
into beamlets of the equal dimensions. Intensity is constant within each individual 
beamlet. But different beamlet may have different intensity. The optimization 
process minimizes the weighted sum of discrepancy from target prescription 
dose and OAR constraint dose by adjusting the intensity level of each beamlet. 
The final fluence maps are generated when the desired dose distribution is 
achieved. The smoothing function is applied in both directions of the fluence 
before leaf motion calculations to improve deliverability of the fluence and 
minimize the beam-on time.  The leaf sequencing is calculated to convert the 
fluence map into deliverable MLC leaf motion, taking MLC limitations and design 
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into consideration. The leaf motion can be calculated for segmented or dynamic 
delivery. The segmented MLC motion sequence has multiple static apertures. 
The beam is turned on when the leaves stop and is turned off when the leaves 
move to the next segment. The leaves move continuously with variable speeds 
while the beam is on with a variable dose rate, for the dynamic MLC sequence 
delivery.   
 
Figure 15: A. At least 99% of PTV receives at least 8000cGy. B. The maximum dose received by PTV 
should be less than 8200cGy. C. No more than 10% of the rectum receives more than 7000cGy. 
 
 The initial guess accumulated dose of the previously treated sessions is 
used as a baseline for the new optimization and the objective function is 
minimized for the remaining fractions. The new optimal fluence map is generated 
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and dose is recalculated for the remaining sessions to assure that the 
composited dose deposition satisfies the original prescription.  
 
3.3 Results & Discussion 
3.3.1 HU-ED Calibration for CBCT 
 
The average HU number was plotted against the known relative electron density 
for both SIM-CT and CBCT (Fig.16). Error bars showed the standard deviation of 
HU numbers of the measurements. The two curves were well correlated. Also the 
HU number calibration accuracy depended on the phantom insert material. The 
larger discrepancy was shown in the high density region. The high density insert 
made of Teflon has been reported as a less than ideal tissue substitute (Craig, 
Brochu and Vandyk 1999). In the human bony structures, HU would be higher for 
the same electron density due to higher atomic numbers of calcium. The non-
linear correction was carefully examined regarding the effect of HU difference on 
dose calculation using CBCT.  
3.3.2 Dose calculation on CBCT 
 
3.3.2.1 Four-field box calculation with and without inhomogeneity correction 
 The traditional 3D plan of four opposed fields using 6MV beam was 
calculated on the rando phantom image with and without inhomogeneity 
correction. If the inhomogeneity correction was turned off, the Dmean between 
SIM-CT and CBCT was only 0.1% different and Dmax was 0.3% different in the 
target. The difference of Dmin was 1.2%. The isodose distribution and DVH 
comparison between the two images sets were compared in Fig. 18.   
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Figure 16: HU and relative electron density for SIM-CT vs. CBCT. 
 
 When the inhomogeneity correction was on, the minimum dose showed 
up to 5% difference for the prostate and OAR. However, the mean doses agreed 
very well between SIM-CT and CBCT. Table 8 shows dose statistics comparison 
of the two plans. The isodose distribution and DVH were displayed in Fig.18. The 
dose distribution deviated slightly between CBCT and SIM-CT. However, the 
similarity between the two plans was well within the clinical tolerance.  
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(a)       (b) 
 
 
 
(c) 
 
Figure 17: 3D plan without inhomogeneity correction.  (a) Isodose distribution in the SIM-CT.  (b) 
Isodose distribution in the CBCT. (c) DVH comparison of prostate (red), rectum (brown), and 
bladder (blue) between SIM-CT (square) and CBCT (triangle). 
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   (a)      (b) 
 
     (c)        
Figure 18: 3D plan with inhomogeneity correction.  (a) Isodose distribution in the SIM-CT. (b) 
Isodose distribution in the CBCT. (c) DVH comparison of prostate (red), rectum (brown), and 
bladder (blue) between SIM-CT (square) and CBCT (triangle). 
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 Table 8: Minimum dose, maximum dose and mean dose for prostate, rectum and bladder 
using four-field box technique with inhomogeneity correction 
 
 
 
 
Dmin 
Prostate 
Dmax 
 
Dmean 
 
Dmin 
Rectum 
Dmax 
 
Dmean 
 
 
 
Dmin 
Bladder 
Dmax 
 
Dmean 
SIM-CT 89.1% 103.1% 99.2% 26.3% 102.1% 61.9%  40.5% 100.5% 59.3% 
CBCT 94.1% 103.4% 99.5% 31.8% 102.6% 61.9%  43.7% 100% 59.1% 
 
3.3.2.2 IMRT Dose Calculation 
 The 9 uniformly spaced fields IMRT plan that is routinely used for prostate 
treatment was applied to the rando phantom for comparison between 
calculations based on SIM-CT and CBCT.  The plan was optimized and 
calculated on SIM-CT. And the plan with same fluence and MU was recalculated 
on a co-registered CBCT image. The comparison between the two plans is 
summarized in table 9 and Fig19. CBCT plan showed slightly more 
inhomogeneous dose distribution with 1% higher maximum dose and 5% higher 
minimum dose. The prescription isodose coverage on target correlated well 
between SIM-CT and CBCT. Rectum maximum dose calculated on CBCT image 
was 1.6% less than that calculated on SIM-CT. Bladder dose showed more 
discrepancy. The maximum dose had about 17% difference and mean dose had 
about 1% difference.  
 
 
Table 9: Minimum dose, maximum dose and mean dose for prostate, rectum and bladder using 9 
fields IMRT 
 
 
 
 
Dmin 
Prostate 
Dmax 
 
Dmean 
 
Dmin 
Rectum 
Dmax 
 
Dmean 
 
 
 
Dmin 
Bladder 
Dmax 
 
Dmean 
SIM-CT 70.2% 102.7% 99.2% 3.3% 97.6% 18.3%  4.3% 99.3% 18.4% 
CBCT 75.2% 103.6% 99.6% 3.4% 96.0% 18.2%  4.5% 82.6% 17.1% 
 
 
 
 
65 
 
 
 
 
 
   (a)      (b) 
 
      (c) 
 
 
Figure 19: 9 fields IMRT plan.  (a) Isodose distribution in the SIM-CT. (b) Isodose distribution in the 
CBCT. (c) DVH comparison of prostate (red), rectum (brown), and bladder (blue) between SIM-CT 
(triangle) and CBCT (square). 
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3.3.3 DIR and Validation 
 
3.3.3.1 DIR and Validation on Computer Generalized Pelvis Phantom 
 The parameters for the DIR were tuned and the results were evaluated 
based on the computer generated pelvis phantom (Fig.20). The phantom image 
grid had 160x160x160 voxels with voxel size 1mm in all three dimensions. There 
were geometrical shapes in the image that represent bladder, rectum, prostate 
and femoral heads. The deformable phantom images were derived based on the 
DVF created from DIR on a patient (Zhong, Kim and Chetty).  
 
  (a)      (b) 
Figure 20: The pelvis phantom used for the evaluation of DIR. (a) the fixed image, (b) the moving 
image which is derived from known DVF 
 
 The parameters to achieve the phantom result are listed in table 10 and 
were applied to DIR between SIM-CT and CBCT for all patient treatment 
sessions. The deformed image was generated [Fig.21(a)] and compared to the 
fixed image [Fig.21(b)]. The image registration error was difficult to detect by 
visual comparison in such case. Since DVF was already known to reconstruct the 
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deformed image, DIR result could be quantitatively evaluated voxel by voxel, by 
comparing DVF created from B-Spline registration and the known DVF.  
 
Table 10: B-Spine registration tuned parameters 
 
Image Resolution Levels  4 
Mutual Information Number of spatial samples 
at each level  
4096, 4096, 8192, 16384 
Number of grey levels  16, 32, 64, 64 
B-Spline Interpolator Each resolution level  1, 1, 1, 1 
Final Deformation 3 
Optimization Maximum number of 
iterations at each level 
8000, 8000, 8000, 8000 
Transformation B-Spline Grid Spacing  10x10x5 voxels 
 
 
 
  
  (a)      (b) 
Figure 21: B Spline DIR on pelvis phantom. (a) the deformed image from the moving image, (b) the 
fixed image 
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 Fig. 22 demonstrated the B-Spline registration accuracy. The agreement 
was within sub millimeter for all voxels along the central line from anterior to 
posterior. A larger discrepancy (over 1mm) was observed at the anterior 
boundary region. It showed that the error was increased in the large deformation 
region at the boundary for the B-Spline registration.  
 
 
 
Figure 22: DVF Displacement of benchmark and B-Spline of each voxel in AP direction.  
 
3.3.3.2 DIR and Validation on Prostate Patients 
 Deformable registrations were performed between CBCT and SIM-CT for 
all fractions of five patients. The registration errors were detected by three 
methods for a comprehensive evaluation. Since all the patients were implanted 
with three fiducial markers, the relative positions of the markers between the 
SIM-CT and the deformed CBCT were calculated to evaluate the registration 
error. The registration error in the rigid registration was also calculated for 
comparison.  
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Figure 23: The displacement of the three seeds for each fraction after DIR and rigid registration. (a) 
seed 1 offset between SIM-CT and deformed CBCT in Rt Lat-Lt Lat, Anterior-Posterior, Superior-
Inferior direction, (b) seed 1 offset for the rigid registration in all three directions, (c) seed 2 offset 
between SIM-CT and deformed CBCT, (d) seed 2 offset for the rigid registration, (e) seed 3 offset 
between SIM-CT and deformed CBCT, (f) seed 3 offset for the rigid registration. Blue bar is L-R 
direction. Red bar is A-P direction. Yellow bar is S-I direction. 
 
The offset of the seed was calculated by calculating the difference of voxel 
index at the center of the seed between the fixed image and the deformed image. 
The voxel dimension in z direction was 3mm, which was the slice thickness of CT 
scan. It was larger than the voxel size of 1.07mm in x and y planes. Therefore, 
the displacement was larger in superior-inferior direction, even though the voxel 
index offset was similar, compared to the other two directions. The comparison of 
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the seed position accuracy between DIR and rigid registration is shown in Fig. 23. 
The bar showed the offset in mm comparing the seed position of the SIM-CT and 
registered CBCT for each fraction. The offset measurement was skipped if the 
CBCT was not performed at the beginning ot the treatment session due to some 
technical problems. The seed positions correlated very well between SIM-CT and 
deformed CBCT after DIR. The DIR results demonstrated that this method was 
more accurate than the rigid registration. The mean and standard deviation were 
calculated for each seed in three dimensions after the rigid registration and DIR 
and are shown in table 11. The mean and standard deviation in left-right direction 
was 0 mm and 1 mm correspondingly. But the mean was 2-4mm in the ant-post 
and sup-inf directions and the standard deviation was about 2 mm. After DIR, the 
mean in all three directions became 0 and the standard deviation was less than 
one millimeter.      
Table 11: Statistics of seeds offsets in all three dimensions after rigid registration and DIR 
 
  X (mm) Y (mm) Z (mm) 
Rigid 
Seed1 0±1.16 3±2.06 3±2.48 
Seed2 0±1.21 3±1.87 4±2.6 
Seed3 0±1.50 -2±2.14 4±2.47 
DIR 
Seed1 0±0.40 0±0.47 0±0 
Seed2 0±0.51 0±0.54 0±0.5 
Seed3 0±0.50 0±0.52 0±0.50 
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 Evaluation of seed positions could provide quantitative analysis of the 
accuracy of DIR. However, three seeds could not represent the entire target 
volume information. It was not a valid strategy to validate DIR by relying on 
seeds only. Visual comparison of SIM-CT and deformed CBCT slice by slice was 
a good supplemental method to validate the registration qualitatively. But it was 
time consuming and a subjective method. Also it was difficult to detect errors in a 
millimeter range with a naked eye. However, the UE was able to detect the 
registration error automatically and quantitatively in 3D. The UE value was 
derived by the assigned DVF on the vertices of image grid in three directions. 
The UE image was reconstructed for the sampling voxels and the value was 
taken by averaging the number in three directions. The darker region 
represented lower UE and the brighter region showed higher UE.  The lower the 
value of UE was, the higher the quality of DIR was achieved. To reduce the 
calculation time and to focus on the ROI, the UE image was cropped to the 
prostate and OARs nearby. The corresponding SIM-CT images, deformed CBCT 
images and UE images were sampled in Fig.24 for validation of DIR. There was 
a brighter region in the UE image shown in the first row, which indicated higher 
UE. It was also observed that there was a distortion in the seminal vesicles in the 
deformed CBCT image compared to the SIM-CT image.  The UE value was 
pretty low in the prostate region, which indicated good performance of the image 
fusion. UE calculated by a finite element based framework could be a very 
effective tool to evaluate DIR in clinical settings. DIR between SIM-CT and CBCT 
for all fractions were validated by three different ways for a comprehensive 
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evaluation. The generated transformation matrix was used for the dose 
reconstruction. 
 
 
 (a)    (b)    (c) 
Figure 24: DIR validation. (a) SIM-CT images with every 9mm spacing, (b) corresponding deformed 
CBCT images (c) the cropped UE images in the ROI. 
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3.3.3.3 Dose Reconstruction 
 The dose calculated on CBCT could be warped by applying transformation 
matrix. The transformation matrix was based on the B-Spline grid in DIR. The 
reconstructed dose would have same dimension of image grid. In order to 
accumulate the dose and compare with the planned dose, the warped dose was 
resampled using B-Spline interpolation to match dose grid size calculated in SIM-
CT. One example was shown in Fig.25. Fig.25 (a) showed one dose plane 
calculated in CBCT. The dose matrix size was 159x111x53. The warped dose in 
Fig.25 (b) had dimension 512x512x75 which was same as SIM-CT image size. It 
was resampled to the dose grid size calculated for SIM-CT which was 
159x110x75.         
 
Figure 25: Dose reconstruction. (a) dose calculated on CBCT (b) warped dose by applying 
transformation matrix (c) resampled dose to match dose grid size in SIM-CT. 
 
 After the doses calculated for each treatment session were warped and 
resampled, they can be directly added up since all of them had same grid size 
(Fig.26). If CBCT was not acquired for a certain fraction, the single fraction 
planned dose was used as a substite. The accumulated doses at any treatment 
session were calculated and compared to the planning dose to assess the 
ongoing treatment dose deposition. Re-optimization could be scheduled if the 
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target coverage was not achieved by a specified fraction or an OAR has received 
the dose over the tolerance limit.  
 
Figure 26: Warped dose for each treatment session was accumulated to generate total delivered dose 
at any fraction. 
 
3.3.4 Target Evaluation 
The isodose distributions between a treatment plan (plan) and a real 
delivery (real) were compared slice by slice in three different views for each 
patient. Fig.27 represented the comparison between a planned dose and a 
delivered dose for the patient #4. The isodose distributions in the two cases were 
very close to each other in all three margin settings. The CTV was well covered 
by the prescription dose in all cases. The maximum and minimum doses were 
different slightly in the CTV. Rectum and bladder doses varied a lot in each case.  
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Figure 27: Isodose comparison between “plan” and “real”. (a) plan dose distribution with PTV 
margin 10/6 mm, (b) real dose distribution to plan with PTV margin 10/6 mm, (c) plan dose 
distribution with PTV margin  5/3 mm, (d) real dose distribution to plan with PTV margin 5/3 mm, 
(e) plan dose distribution with PTV margin 3 mm, (f) real dose distribution to plan with PTV margin 
3 mm. 
 
Mean, minimum and maximum doses to CTV for each patient are 
summarized in table 12. With 10 mm margin, planned dose statistics for the CTV 
were very close to the real one for all five patients. Differences of mean, 
minimum and maximum doses of CTV were all within 2%. When the margin was 
reduced to 5/3 (everywhere/posterior) mm, CTV minimum dose showed larger 
discrepancy and the difference was about 5% for three patients and 1% for the 
other two. CTV mean and maximum doses were in agreement within 2%. When 
the margin moved to 3mm, the difference of CTV minimum dose was 4-7% while 
mean and maximum doses were still within 2%. As the margin was reduced, a 
76 
 
 
 
tiny portion of CTV could be underdosed since it might move out of the treatment 
fields in some fractions.  However, it did not have a big clinical impact because 
underdosed region was very small. Sometimes there were just several voxels 
that were moved outside of the prescription isodose line. For all five patients, real 
mean doses to CTV were all within 98% of planned mean dose in 3 mm margin 
setup.  
Table 12: Dose statistics comparison of CTV between planned dose and real dose at three different 
margin settings 
 
 Patient 
Plan 
Dose 
10/6  
Real 
Dose 
10/6 
%Diff 
Plan 
dose 
 5/3  
Real 
Dose 
5/3 
%Diff 
Plan 
Dose 
3  
Real 
Dose 
3 
%Diff 
1 
Min Dose 7656 7749 1.2% 7583 7508 -1.0% 7435 7131 -4.1% 
Mean Dose 7871 7891 0.3% 7872 7871 0.0% 7933 7837 -1.2% 
Max Dose 8234 8283 0.6% 8290 8231 -0.7% 8252 8135 -1.4% 
2 
Min Dose 7903 7997 1.2% 7990 7617 -4.7% 7733 7193 -7.0% 
Mean Dose 8357 8277 -1.0% 8465 8367 -1.2% 8497 8362 -1.6% 
Max Dose 8766 8625 -1.6% 8886 8745 -1.6% 8895 8746 -1.7% 
3 
Min Dose 7629 7622 -0.1% 7613 7240 -4.9% 7601 7276 -4.3% 
Mean Dose 7761 7761 0.0% 7784 7783 0.0% 7809 7791 -0.2% 
Max Dose 7933 7932 0.0% 7964 7932 -0.4% 7961 7930 -0.4% 
4 
Min Dose 8083 8018 -0.8% 8033 7935 -1.2% 8100 7800 -3.7% 
Mean Dose 8205 8103 -1.2% 8239 8131 -1.3% 8246 8130 -1.4% 
Max Dose 8359 8229 -1.6% 8417 8297 -1.4% 8417 8284 -1.6% 
5 
Min Dose 7589 7690 1.3% 7257 7629 5.1% 7227 7529 4.2% 
Mean Dose 7852 7808 -0.6% 7853 7794 -0.8% 7858 7796 -0.8% 
Max Dose 8102 7974 -1.6% 8130 7967 -2.0% 8136 8013 -1.5% 
 
 PTV dose showed much larger discrepancy between the planned dose 
and the real dose. Generally, PTV dose coverage offset increased more as the 
margin became smaller.  Smaller margin could significantly reduce dose to OARs. 
But this is accompanied by a higher risk to miss the target. Many factors could 
account for inter-fraction motion. It was difficult to give a universal margin which 
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was suitable for all patients. DVH comparisons for each patient are presented in 
Fig. 28-32. PTV (pink), CTV (red), rectum (brown) and bladder (blue) were 
plotted to compare planned and real doses. The upper left figure shows the plan 
with 10 mm margin. The upper right figure shows the plan with 5/3 mm margin. 
The lower figure is 3 mm margin. The data for the five patients showed that the 
patient preparation was an important factor in controlling the inter-fraction motion. 
All five patients were instructed on the bowel preparation, and how to maintain 
their rectum and bladder filling for each treatment. The patients were scanned 
with CBCT and corrected for the setup offset for each fraction. If the organs 
showed larger deformation, patient were taken off the table and instructed to 
correct the situation by visiting a bathroom and drinking more water afterwards to 
maintain the bladder filling.  However, the results showed that the real PTV dose 
matched planned dose within 1% for each margin setting for patients 1 and 5. 
Patient 2 showed a highest discrepancy with the PTV dose coverage. The 
volume covered by prescription line was 8% less with 5 mm margin and 11% less 
with 3 mm margin. That patient had more difficulty following the instructions; 
therefore there was more tissue deformation which could not be corrected by the 
rigid transformation.    
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Figure 28: DVH comparison for the three different PTV margins between the treatment plan and the 
real plan of the patient 1. PTV is the pink line; CTV is the red line; Rectum is the brown line; 
Bladder is the blue line. (a) With the PTV margin of 10/6 mm; (b) With the PTV margin of 5/3 mm; 
(c) With the PTV margin of 3mm.   
 
 
 
Figure 29: DVH comparison for the three different PTV margins between the treatment plan and the 
real plan for the patient 2. PTV is the pink line; CTV is the red line; Rectum is the brown line; 
Bladder is the blue line. (a) With the PTV margin of 10/6 mm; (b) With the PTV margin of 5/3 mm; 
(c) With the PTV margin of 3mm. 
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Figure 30: DVH comparison for the three different PTV margins between the treatment plan and the 
real plan for the patient 3. PTV is the pink line; CTV is the red line; Rectum is the brown line; 
Bladder is the blue line. (a) With the PTV margin of 10/6 mm; (b) With the PTV margin of 5/3 mm; 
(c) With the PTV margin of 3mm. 
 
 
 
Figure 31: DVH comparison for the three different PTV margins between the treatment plan and the 
real plan of patient 4. PTV is the pink line; CTV is the red line; Rectum is the brown line; Bladder is 
the blue line. (a) With the PTV margin of 10/6 mm; (b) With the PTV margin of 5/3 mm; (c) With the 
PTV margin of 3mm. 
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Figure 32: DVH comparison for the three different PTV margins between the treatment plan and the 
real plan for the patient 5. PTV is the pink line; CTV is the red line; Rectum is the brown line; 
Bladder is the blue line. (a) With the PTV margin of 10/6 mm; (b) With the PTV margin of 5/3 mm; 
(c) With the PTV margin of 3mm. 
 
 TCP for CTV was also calculated to evaluate tumor control in different 
margin settings.  PTV was not used for the evaluation since the volume was 
different for each margin. There were many uncertainties for TCP parameters. A 
lot of debates have been going on in the literature regarding α/β value for 
prostate, surviving fraction and clonogenic cells density. To avoid any bias, a 
broad range of numbers was used for TCP evaluation. α/β ratio was varied from 
1.5 to 9.5 with an increment of 1. SF2 values were 0.5 and 0.6, the most probable 
surviving fraction of tumor cells at 2Gy. The cell density was 10N /cm3 where N 
ranged from 3 to 6.  
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Figure 33: TCP value vs.  α/β ratio of the plan and the real dose delivery for the three margins for the 
patient 1. N0 =10,000/cm3. (a) SF2 is 0.5. TCP is 1 for each α/β value in all plans; (b) SF2 is 0.6. TCP 
difference is within 1% across the range of α/β ratio in each plan. Solid lines connecting the data 
points are used for the visibility only. 
 
 Since the prescription dose to all five patients was either 1.8Gy or 2Gy, 
there was no hypofraction radiation in the study. The effect of α/β ratio to TCP 
was minimal. TCP was 100% across α/β region from 1.5 to 9.5 if SF2 was 0.5 
and N0 was 104 (Fig.33 (a)). And the difference was only 1% if SF2 was 0.6 
(Fig.33 (b)). α/β ratio of 4.5, which was the average TCP value across the range, 
was used for all subsequent calculations.  
 When SF2 was 0.5, TCP for all plans of the five patients was within 99% in 
either the planned dose or the real dose. And TCP was almost independent of 
the clonognic cell density, within 0.1% variation from 103 to 106 /cm3. When SF2 
was 0.6, TCP value was patient and N0 dependent. If the tumor cell density was 
less than 105/cm3, then the TCP was close to 1 for plans with different margins 
for each patient. As the cell density increased from 105 to 106, TCP dropped at 
various rate for each patient. TCP was between 0.81 and 0.85 for two patients 
and over 0.9 for the other three patients. For different margin plans, TCP value 
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varied within 1-3%.  Also TCP in the real dose agreed within 5% of the value in 
the plan for all patients.  
 
Figure 34: TCP vs. N0 evaluation for all six plans for the five patients. N0 is in log scale ranging from 
103 to 106.  TCP value of six plans was compared against each other to determine the margin effect 
and the real dose delivery against the plan.  Solid lines connecting the data points are used for the 
visibility only. 
  
There are several randomized clinical trials published to compare 
hypofractionated and normofractionated radiotherapy (Lukka et al. 2005) (Pollack 
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et al. 2006) (Yeoh et al. 2006).  Due to the nature of the lower α/β ratio of 
prostate cancer, the hypofractionated radiotherapy can achieve better 
therapeutic gain since prostate are more sensitive to fractionation than nearby 
late-responding normal tissues. However, there are still a lot of debates about the 
α/β value of prostate cancer due to radiobiological uncertainties (Dasu, 2007). 
Brenner calculated the α/β value 1.5Gy (Brenner and Hall, 1999) which is similar 
to the value obtained from Fowler (Fowler et al. 2001). Wang et al obtained a 
value of 3.1Gy (Wang et al. 2003). At the same time, the risk of acute toxicity are 
increased by reducing the total treatment time. The advantage of using 
hypofractionation stills needs to be further investigated using randomized trials 
with better understanding of the α/β value of prostate cancer.  
3.3.5 Normal Tissue Evaluation 
 Rectum and bladder doses were also compared to evaluate the tissue 
toxicity for each patient. As the margin was reduced from 10 mm to 5/3 mm or 
from 5/3 mm to 3 mm, rectum and bladder doses were reduced significantly. 
However, the maximum dose in rectum and bladder were same in the in vicinity 
of PTV in all scenarios.  
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Table 13: Dose statistics comparison for rectum between the planned dose and the real dose for three 
different margin settings 
 
 Patient 
Plan 
Dose 
10/6 
Real 
Dose %Diff 
Plan 
dose 
Real 
Dose %Diff 
Plan 
Dose 
Real 
Dose %Diff 
10/6  5/3  5/3 3 3 
1 
Min Dose 355 314 -11.5% 236 277 17.4% 206 216 4.9% 
Mean Dose 3355 3892 16.0% 2940 3490 18.7% 3012 3383 12.3% 
Max Dose 8104 8161 0.7% 8069 8154 1.1% 8001 7950 -0.6% 
2 
Min Dose 243 281 15.6% 189 228 20.6% 186 202 8.6% 
Mean Dose 3697 4546 23.0% 3215 4155 29.2% 2884 3877 34.4% 
Max Dose 8717 8579 -1.6% 8690 8610 -0.9% 8704 8556 -1.7% 
3 
Min Dose 246 544 121.1% 200 353 76.5% 162 289 78.4% 
Mean Dose 3563 5074 42.4% 2771 4206 51.8% 2669 4153 55.6% 
Max Dose 7828 7811 -0.2% 7805 7797 -0.1% 7840 7717 -1.6% 
4 
Min Dose 255 257 0.8% 194 197 1.5% 183 176 -3.8% 
Mean Dose 4089 4534 10.9% 3437 3981 15.8% 3055 3656 19.7% 
Max Dose 8337 8204 -1.6% 8267 8214 -0.6% 8277 8216 -0.7% 
5 
Min Dose 301 443 47.2% 229 313 36.7% 206 260 26.2% 
Mean Dose 4152 4983 20.0% 3360 4340 29.2% 2973 3984 34.0% 
Max Dose 7939 7848 -1.1% 8061 7869 -2.4% 7998 7872 -1.6% 
 
 The rectum dose statistics is summarized in table 13 for all 6 plans for five 
patients. The maximum dose delivered to rectum was at the same level as the 
planned dose. Different margin plans had similar CTV maximum dose located at 
the posterior edge, closest to rectum. The mean dose to rectum increased 
between 10% - 25% for four patients and over 40% for one patient, which had 
relatively small rectum volume.  This analysis showed that margin reduction is a 
very effective tool in reducing the rectal dose. 
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Figure 35: Rectum EUD of five patients based on Emami’s data where TD50=80Gy, n=0.12, m=0.15.  
Blue bars represent EUD based on the real dose. Red bars represent EUD based on the planned dose.  
 
 EUD and NTCP were calculated to evaluate reaction of rectum to radiation. 
Rectal EUD in the real delivery and the plan were compared in Fig.35 at the 
three margin settings. EUD increased 5-7% in the real delivery of plan with 10/5 
mm margin for all five patients. As the margin wad reduced, the percent 
difference increased to 5-14%.  For the larger margin, there was more of the 
rectum volume overlapping with the PTV. Therefore, variations of the rectal dose 
caused by the deformations were smaller.  
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 NTCP was calculated based on Emami’s fitting data to evaluate rectal 
complication and is shown in Fig.36. Margin reduction from 10/6 mm to 5/3 mm 
was a very effective way to reduce GI toxicity. NTCP was decreased by 6% on 
average for each patient. As the margin was further reduced from 5/3 mm to 
3mm, NTCP was decreased by 2% on average. Patient 2 showed highest 
increase of NTCP which was about 10% of the real dose delivery. On average, 
NTCP was increased by 6% for the real dose relative to the planned dose.  
 
Figure 36: NTCP comparison for rectum between the real dose and the planned dose for the three 
margin settings.  Each figure shows the real NTCP (filled square) vs. the planned NTCP (square). 
The X-axis  shows the value of each margin. Solid lines connecting the data points are used for the 
visibility only. 
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Figure 37: NTCP comparison of late rectal bleeding between the real dose and the planned dose for 
the three margins. Grade 2/3 late bleeding was calculated based on parameters where TD50=81.9Gy, 
n=0.23, m=0.19. Grade 3 late bleeding was calculated based on parameters where TD50=78.6Gy, 
n=0.06, m=0.06. Markers with filled square showed NTCP of real grade 2/3 bleeding. Markers with  
square showed NTCP of planned grade 2/3 bleeding. Markers with filled triangle represented NTCP 
of real grade 3 bleeding only. Markers with triangle represented NTCP of planned grade 3 bleeding 
only. Solid lines connecting the data points are used for the visibility only. 
 
 Rectal bleeding was also evaluated based on Italian multi-centric data. 
Both grade 2/3 and grade 3 alone rectal bleedings were estimated and presented 
in Fig.37. NTCP calculated based on the real dose distribution indicated that the 
possibility of having rectal bleeding with grade level 2 or 3 was less than 10%.  
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When the margin was 3 mm, NTCP was about 4% on average of real dose and  
1% of planned dose of rectal bleeding. When the margin was 5/3 mm, NTCP was 
about 6% of the real dose and 2% of the planned dose. When the margin was 
enlarged to 10/6 mm, NTCP was about 9% of real dose and 4% of planned dose. 
Patient 2 showed very high risk of bleeding, about 18% for grade 3 level.  
 Similar biological evaluation was performed for bladder. Emami’s data 
were used for EUD calculation (Fig.38). EUD of the real dose was 3% - 9% 
higher than that of the planned dose for thes patient 1-3, 11%-20% higher for the 
patients 4-5. Also, EUD increasing rate showed a negative correlation with 
margin. As the margin was reduced, the EUD difference became larger. If the 
same parameters were used for NTCP calculation to evaluate symptomatic 
bladder contracture, NTCP was zero for all cases. Since bladder dose was 
relatively low, there was no risk of contracture when the dose for the complication 
probability of 50% was 80Gy. Not many papers have been published to discuss 
GU toxicity. There are two reasons. First, the dose volume information was not 
reliable for bladder which volume had varied significantly between fractions. 
Second, it took a longer time to follow up late GU toxicity since it increased 
continuously with time. Data published (TD50 =77.6Gy, n=0.00995, m=0.022) by 
Cheung was used for NTCP calculation to evaluate late GU toxicity with grade 
equal or greater than 1. Since n was very small, bladder was considered a serial 
organ. The complication was directly related to the Dmax of the bladder. NTCP 
was smaller in the real dose delivery since the real Dmax was smaller than the 
planned Dmax. Patient 3 had almost no complications while the patient 2 had   
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100% possibility to have GU toxicity greater than grade 1. It was because Dmax 
was about 80Gy for the patient 2 and only 74Gy for the patient 3. Smaller 
margins could not reduce late GU toxicity effectively since Dmax was at the same 
magnitude in the bladder no matter which margin was applied. 
 
Figure 38: Bladder EUD of five patients based on Emami’s data where TD50=80Gy, n=0.5, m=0.11.  
Blue bar represented EUD based on real dose. Red bar represented EUD based on planned dose.  
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Figure 39: NTCP comparison of bladder between the real dose and the planned dose for three 
margins.  Each figure showed real NTCP (filled square) vs. planned NTCP (square). The marker 
showed the value for each margin. Patient 3 (c) and 5 (e) had very low NTCP, less than 20% for 
10mm margin plan. Patient 2 (b) showed almost 100% complication.  Patient 1 (a) and 4 (d) were in 
the middle range level. NTCP of the real dose was higher than that of planned dose. Solid lines 
connecting the data points are used for the visibility only. 
 
3.3.6  Re-Optimization 
 There are typically 40-42 treatment fractions to treat prostate cancer. Re-
optimization schedule was a tradeoff between the labor intensity and an optimal 
isodose coverage. On one side, it was not necessary to re-optimize treatment 
plan at every single fraction since deviation in one fraction was very minimal. On 
the other side, if the optimization was not performed for several fractions and an 
OAR received much higher dose than expected, it would be difficult to limit the 
dose to the OAR in the re-optimization while maintaining the PTV dose coverage. 
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Schedule for optimization was studied to evaluate the consequences of dose 
volume effect.  
 
 
Figure 40: DVH comparison between real dose and planned dose at (a) 5th fraction, (b)10th fraction, 
(c) 15th fraction, (d)20th fraction, (e) 25th fraction, (f) 30th fraction, (g) 35th fraction, (h) 42nd fraction. 
The upper DVH lines of rectum and bladder showed the real dose and the lower ones were the 
planned dose. The discrepancy was accumulated over fractions. PTV and CTV DVH did not have 
large deviation.  
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 The accumulated dose at every 5th fraction of the real delivery was 
compared with the planned dose for patient1. DVHs in Fig.40 showed that the 
target coverage over fractions was very close while the OAR had larger dose 
deviation. The dose discrepancy at first five fractions was very minimal and it 
increased significantly at 10th fraction due to larger organ deformation in those 
treatment fractions. Once the large deviation happened, it would add up and 
contribute to even larger discrepancy in the following fractions. Re-optimization 
was necessary then to eliminate overdose of rectum and bladder.  
 
Figure 41: DVH comparison planned dose and accumulated dose at every ten fractions plus re-
optimized dose for the remaining fractions. (a) Accumulated dose at 10th fraction plus re-optimized 
dose of the rest 32 fractions. (b) Accumulated dose at 20th fraction plus re-optimized dose of the rest 
22 fractions. (c) Accumulated dose at 30th fraction plus re-optimized dose of the rest 12 fractions. (d) 
Accumulated dose at 40th fraction plus re-optimized dose of the rest 2 fractions.  
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 Fig. 41 compared the target and the OAR dose after optimization and the 
planned dose at different optimization schedule. Re-optimization was performed 
at 10th, 20th, 30th, and 40th fraction to evaluate the effectiveness of limiting the 
OAR dose while maintaining the target coverage. Reconstructed dose was 
added to dose of the remaining fractions after the optimization to show the total 
dose that a patient would receive. It showed that if the plan was re-optimized at 
10th (Fig.41 (a)) or 20th fraction (Fig.41(b)), the total doses to the rectum and the 
bladder were very similar to the planned dose with minor deviations. CTV and 
PTV coverage was matched with a prescription very well. If the plan was re-
optimized at 30th fraction (Fig.41 (c)), since there was a large deviation between 
the reconstructed dose and the planned dose to OAR, optimization could not limit 
OAR dose to the original plan with only 12 fractions left. If the re-optimization was 
conducted at the 40th fraction (Fig.41 (d)), it was impossible to apply optimization 
in the last 2 fractions. Large deviation of the total dose to bladder and rectum still 
existed while dose inhomogeneity to PTV was significantly increased due to 
constraint setting in optimization to reduce OAR dose. 
3.4 Conclusion 
 The development of CBCT has opened a door to a possibility of acquiring 
a patient’s anatomical information in the treatment position. Over the years since 
CBCT has been used clinically for radiation therapy, the image quality has been 
improved significantly. Not only can CBCT be used for online patient setup, but it 
is  also demonstrated that CBCT can be used for accurate dose calculation at 
certain sites like prostate. DIR has also been studied at multiple institutions and 
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used for clinical evaluation of patient treatments.  Even though DIR of CBCT 
images is still a challenging task, especially for the prostate site, this study 
validates that CBCT images can be reliably fused with helical CT images with a 
proper patient bowel preparation. Three methods are used to evaluate the image 
registration results quantitatively and qualitatively.  With the tools of CBCT and 
DIR, the next generation of radiation treatment – ART has emerged to reduce 
treatment uncertainties. 
 IGRT can effectively assess intra-, inter-fraction motion of target with 
different imaging modalities. However, it cannot compensate for dosimetric 
consequences. The strategy of ART in this study is to (1) calculate dose on each 
CBCT set to know the real dose delivery (2) deform CBCT images to SIM CT 
images (3) re-construct the dose based on a transformation matrix generated 
from DIR (4) re-optimize a patient plan if necessary. With ART, the treatment 
delivery precision can be enhanced even over eight weeks’ treatment periods. 
Five patients with prostate cancer have been studied retrospectively under IRB 
approved protocol. Different evaluation methods such as DVH, isodose lines, and 
radiobiological model were applied to compare the reconstructed dose and the 
planned dose.  
 The reason to use ART was that prostate position and shape varies daily 
mainly due to rectal and bladder filling. MD Anderson study showed that the local 
control rate could be reduced by about 25% in distended rectum patients 
compared to empty rectum (Crevoisier et al 2005). Such clinical evidence 
confirmed the importance of targeting prostate precisely during both the planning 
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and the treatment. However, IGRT along could perform such targeting. Several 
studies have shown that TCP can be improved 5-10% with IGRT. In our study, 
ART did not show the improvement of TCP if the patient was setup with CBCT. 
However, EUD of rectum and bladder was increased a lot due to tissue 
deformation, which varies daily. NTCP of rectum was increased by 6% on 
average in the reconstructed dose. Grade 2 and grade 2/3 rectal bleeding were 
also evaluated based on the reconstructed dose for each patient. There was no 
difference in bladder complications between the planned dose and the 
reconstructed dose since late GU toxicities depend mainly on Dmax.  
 With the advantage of ART, CTV margins could be further reduced to 
preserve critical organs surrounding the target. Two different margins 5/3 mm 
and 3mm were used in re-planning to determine the effectiveness of margin 
reduction. TCPs were within 3% among all three margins for each patient. 
However, small margin could reduce dose to OAR significantly. NTCP of rectum 
was reduced by 6% with 5/3 mm margin plan and 8% with 3mm margin plan. 
Late GU toxicity remains the same since Dmax was at same magnitude in each 
margin plan.  
 Re-optimization schedule was also studied to achieve a tradeoff between 
the labor intensity and an ideal treatment. The common sense to re-optimize at 
the last fraction was not applicable in reality since if the rectum and the bladder 
were overdosed already, there was no way to push dose back to the planned 
dose. And target dose would be very inhomogeneous if the hard dose limiting 
constraints were imposed on the OAR. On the other hand, there was no 
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necessity to re-optimize at each single treatment since dose deviation was not 
significant. Re-optimization schedule was compared at 10th, 20th, 30th, and 40th 
fraction. It was recommended to re-optimize treatment plan at every 10th fraction. 
ART has a potential to improve the local control rate and to reduce toxicity. It also 
correlates the actually delivered dose to the clinical outcomes, which brings a 
more direct clinical relevance than the conclusions drawn in the published data 
based on the planning dose distribution. Even though it is still in the early stages 
and there are not many data on the issue, ART is definitely a promising treatment 
strategy to improve the fight against cancer.  
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CHAPTER 4: SUMMARY AND FUTURE WORK 
 
CBCT provides volumetric information for daily target localization. Such 
detailed anatomical information can be compared with a treatment plan CT online 
to adjust for setup errors. It is highly beneficial for the treatment of prostate 
cancer over an eight week course of treatment.  CBCT can be used to align the 
prostate which cannot be otherwise visualized in 2D imaging. Also, bladder and 
rectum information can be acquired for a clinical judgment before each treatment. 
The experience of CBCT is very encouraging for soft tissue localization. However, 
since CBCT has to be acquired for each fraction, the accumulated dose can be 
much higher than that of a diagnostic CT. Future, relative biological effectiveness 
(RBE) value of the KV is still under investigation. Dose delivered from CBCT 
should be well understood to be used in the clinic.  
The doses to skin and in phantom are measured with a pelvis rando 
phantom and CIRS phantom using TLD and ion chamber, following the AAPM 
TG61 protocol. CBCT dose over a treatment course of 42 fractions is about 1Gy 
at center, 2Gy at skin and 4Gy to a femoral head. It is much smaller than the 
prescription dose to the target and dose to the peripheral regions. Considering 
the advantage of eliminating the patient setup uncertainty, CBCT provides a 
powerful tool to improve a patient treatment. CBCT images can also be used for 
the post treatment verification of dosimetric effects. ART framework has been 
established to advance the treatment precision to the next level. Dose calculation 
accuracy on CBCT, DIR, radiobiological model and re-optimization schedule are 
addressed carefully. The study has shown that ART can help to better 
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understand the real dose delivery to patients and further reduce the normal 
tissue toxicity.  
 However, there are still some issues with CBCT and ART that need to be 
resolved. The image quality of CBCT needs to be further improved. With a large 
scatter contribution, it is difficult to distinguish and delineate internal organs on a 
CBCT. With dose reduction techniques that are limiting projection data, the poor 
image quality is even more pronounced. Scatter radiation can also cause HU 
non-linearity which degrades the accuracy of dose calculations on CBCT.  Also 
poor image quality reduces the precision of DIR which produces an additional 
uncertainty for dose reconstruction.  Scatter reduction techniques need to be 
developed to improve CBCT image quality.  
It takes several hours to register one CBCT set to SIM-CT using B-Spline 
DIR. Thus it is not feasible to apply it clinically. GPU (graphics processing unit) is 
more effective than CPU for DIR with highly parallel structures. The fusion time 
can be significantly reduced with GPU based DIR. A faster and more accurate 
DIR algorithm needs to be integrated for ART.  
DIR has been evaluated with multiple methods. Verification with implanted 
seeds cannot represent the registration result for the whole volume. Reviewing 
images slice by slice is very time consuming and is subjective due to observer 
variability. UE shows its potential to validate DIR quantitatively and qualitatively 
with an automated algorithm. However, it is still in the early stage of development. 
Future efforts and QA are needed to release it for clinical use.  
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There are many publications discussing radiobiological model for the 
prediction of radiotherapy outcome. However, there are still a lot of uncertainties 
to involve in using such a radiobiological model. Prostate α/β ratio is still under 
debate. TCP and NTCP parameters generated by curve fitting from multiple 
institutions are not applicable universally. There are still implements to using 
radiobiological models as a standard tool to evaluate treatment plans. 
ART has also opened the road for hypofractionation. Different 
hypofractionated schemes have been activated for prostate cancer treatment. 
They vary from 2.3 Gy/fraction in 28 fractions up to 8Gy in 5 fractions. However 
due to current limits on DIR and CBCT image quality, it is hard to distinguish 
prostate and rectal wall with good registration. So it is difficult to escalate the 
dose to very high levels since a small portion of rectal wall may overlap with PTV 
and receive the same dose, which could lead to severe complications, like 
bleeding and fissures. The strategy should focus on limiting dose to the overall 
PTV-rectal wall region in order to escalate the prescription dose to prostate.  
ART can also be applied to other treatment sites such as lung and Head 
and Neck (H&N) etc. However, the current CBCT images of lung scan are poor 
due to motion artifacts and scatter. Neither can it be used for DIR nor it can 
achieve accurate dose calculation. 4D-CBCT with scatter correction needs to be 
developed and evaluated in order to implement ART for lung cancer.  
IMRT has been used for the treatment of H&N cancer extensively in the 
past decade to preserve the surrounding critical organs with high conformality to 
the tumor. However, the dose gradients are very sharp in the H&N plan for organ 
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sparing. Due to the long treatment period (~2 month), the variability of patient 
setup and anatomy change due to weight loss or tumor shrinkage can lead to 
significant dosimetric changes. Ballivy et al. scanned eight H&N patients weekly 
and found out the contralateral parotid and spinal cord dose were higher than 
originally planned. ART can be an effective treatment strategy to discover any 
detriment to target coverage and overdose to the critical organs with patient’s 
anatomic change. The margin reduction and optimization schedule can also be 
investigated using the framework developed. 
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ABSTRACT 
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 ART is a close-loop feedback algorithm which evaluates the organ 
deformation and motion right before the treatment and takes into account dose 
delivery variation daily to compensate for the difference between planned and 
delivered dose. It also has potential to allow further dose escalation and margin 
reduction to improve the clinical outcome. This retrospective study evaluated 
ART for prostate cancer treatment and radiobiological consequences. An IRB 
approved protocol has been used to evaluate actual dose delivery of patients 
with prostate cancer undergoing treatment with daily CBCT. 
 The dose from CBCT was measured in phantom using TLD and ion 
chamber techniques in the pelvic scan setting. There were two major findings 
from the measurements of CBCT dose: (1) the lateral dose distribution was not 
symmetrical, with Lt Lat being ~40% higher than Rt Lat and (2) AP skin dose 
varies with patient size, ranging 3.2-6.1 cGy for patient’s AP separation of 20-33 
cm (the larger the separation, the less the skin dose) but lateral skin doses 
depend little on separations.   
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 Five low risk localized prostate cancer patients were selected for the study. 
The CTV included prostate and 1cm proximal seminal vesicle. PTV was created 
by adding 1 cm margin to CTV except 6 mm posteriorly to limit rectal dose. The 
treatment plans were 7 to 9 fields IMRT. CBCT was acquired before each 
treatment for online image guidance. The rigid registration was performed online 
to fuse CBCT to SIM-CT. The patient position was corrected in three translational 
directions based on registration results.  
 Dose was recalculated on each CBCT set under the same treatment plan. 
DIR was performed between SIM-CT and evaluated for each CT sets. Dose was 
reconstructed and accumulated to reflect the actual dose delivered to the patient. 
Then the adaptive plans were compared to the original plan to evaluate tumor 
control and normal tissue complication using radiobiological model. Different PTV 
margins were also studied to access margin reduction techniques. If the actual 
dose delivered to the PTV deviated significantly from the prescription dose for the 
given fractions or the OAR received higher dose than expected, the treatment 
plan would be re-optimized based on the previously delivered dose.  The optimal 
schedule was compared based on the balance of PTV dose coverage and 
inhomogeneity, OAR dose constraints and labor involved.  
 DIR was validated using fiducial marker position, visual comparison and 
UE. The mean and standard deviation of markers after rigid registration in L-R 
direction was 0 and 1 mm. But the mean was 2-4 mm in the A-P and S-I direction 
and standard deviation was about 2 mm. After DIR, the mean in all three 
directions became 0 and standard deviation was within sub millimeter. UE 
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images were generated for each CT set and carefully reviewed in the prostate 
region. DIR provided accurate transformation matrix to be used for dose 
reconstruction.  
 The delivered dose was evaluated with radiobiological models. TCP for 
the CTV was calculated to evaluate tumor control in different margin settings.  
TCP calculated from the reconstructed dose agreed within 5% of the value in the 
plan for all patients with three different margins. EUD and NTCP were calculated 
to evaluate reaction of rectum to radiation. Rectal EUD increased 5-7% in the 
real delivery of the plan with 10/5 mm margin for all five patients. As the margin 
was reduced, the percent difference increased to 5-14%.  Margin reduction from 
10/6 mm to 5/3 mm was a very effective way to reduce predicted GI toxicity. 
Calculated NTCP was decreased by 6% on average for each patient. As the 
margin was reduced from 5/3 mm to 3mm, NTCP was decreased by 2% on 
average. NTCP calculated based on actual dose distribution indicated that 
possibility was less than 10% to have rectal bleeding with grade level 2 or 3.  
Similar biological evaluation was performed for bladder. EUD of actual dose was 
3% - 9% higher than that of planned dose of patient 1-3, 11%-20% higher of 
patient 4-5.  Smaller margins could not reduce late GU toxicity effectively since 
bladder complication was directly related to Dmax which was at the same 
magnitude in the bladder no matter which margin was applied. 
 Re-optimization was performed at the 10th, 20th, 30th, and 40th fraction to 
evaluate the effectiveness to limit OAR dose while maintaining the target 
coverage. Reconstructed dose was added to dose from remaining fractions after 
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optimization to show the total dose patient would receive. It showed that if the 
plan was re-optimized at 10th or 20th fraction, total dose to rectum and bladder 
were very similar to planned dose with minor deviations. If the plan was re-
optimized at the 30th fraction, since there was a large deviation between 
reconstructed dose and planned dose to OAR, optimization could not limit the 
OAR dose to the original plan with only 12 fractions left. If the re-optimization was 
done at the 40th fraction, it was impossible to compensate in the last 2 fractions. 
Large deviations of total dose to bladder and rectum still existed while dose 
inhomogeneity to PTV was significantly increased due to hard constraints set in 
the optimization to reduce OAR dose. 
 In summary, ART did not show improvements in TCP if the patient was 
setup with CBCT. However, EUD of rectum and bladder was increased 
significantly due to tissue deformation which varied daily. With the power of ART, 
margins added to the CTV could be further reduced to preserve critical organs 
surrounding the target. 
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